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ABSTRACT 
Liver cancer is associated with a very bad prognosis. Oncolytic virotherapy seems a promising 
alternative to standard treatments. Here, I compared; (1) the transduction specificity and efficacy of 
four fibre-modified adenoviruses and the wild type fibre virus, (2) the selectivity and oncolytic 
potency of three conditionally-replicating viruses, and (3) the cytotoxicity of two CD40-ligand 
expressing adenoviruses. The comparisons were done in vitro in liver cancer cell lines and primary 
hepatocytes. The long term goal is to insert the best fibre, and potentially CD40L, into the best 
replication-competent vector. Immunohistochemistry was also performed in liver cancer sections and 
surrounding non-cancer tissues to compare the levels of the viral receptors and CD40 between the 
tumour and the surrounding liver. The Ad5/3 fibre-chimeric virus was found to have the best overall 
transduction efficacy although none of the fibre-modified viruses is expected to be tumour-specific 
according to the results from immunohistochemistry and testing in primary hepatocytes. The 
conditionally replicating viruses were not found to be selective, although these results will need to be 
replicated. The expression of CD40L didn’t have any effect on the viability of the hepatocellular 
carcinoma cell lines in vitro. 
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 Abbreviations and definitions table 
Ad5 Adenovirus serotype 5 
vp Virus particles (calculated with the DNA assay) 
IU Infectious units (calculated with the Adeno-X Rapid Titer Kit from 
Clontech in 293 cells) 
MOI Multiplicity of infection. Expressed as vp/cell or IU/cell 
Absorption time The period of time for incubating the cells with the virus (from adding the 
virus to removing the virus-containing medium) 
Absorption 
volume 
The volume used for infection during the absorption time 
HCC Hepatocellular carcinoma 
ICCA Intrahepatic cholangiocarcinoma 
Non-tumour 
liver 
This term is preferred over “normal” or “healthy” liver as in most cases 
liver cancer develops from a background of chronic liver disease.  
IHC Immunohistochemistry 
Mfi Median fluorescence intensity as determined by flow cytometry  
CPE Cytopathic effect, i.e. rounding and detachment of the cells due to the 
adenoviral infection 
See Table 1 (page 13) for the naming and a short description of the viruses used 
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Liver cancer is a leading cause of cancer death worldwide (2nd in men, 6th in women) and its 
incidence is increasing in many parts of the world [1]. Most patients with hepatocellular carcinoma 
(HCC) are not candidates for potentially curative treatments (surgical resection or transplantation) 
because of the advanced stage of the disease at diagnosis [2]. Sorafenib, the standard treatment option 
for advanced HCC, extends survival by just a few months [3]. Therefore, novel therapies are needed. 
Among them, oncolytic virotherapy seems very promising. Oncolytic viruses are naturally occurring 
or engineered viruses that can selectively infect and kill cancer cells versus normal cells. Furthermore 
they can replicate intratumourally and spread. Among the oncolytic viruses, adenoviruses have been 
extensively studied.  
The adenovirus infection involves many steps: 
1) Binding of the viral capsid to the cell is the first. The viral capsid is an icosahedron (Figure 
1A). The main proteins of the capsid are the homotrimeric hexon proteins. The penton bases 
and the fibre proteins are located at the 12 vertices of the icosahedron. The fibre is a 
homotrimer with three regions: the tail, the shaft and the knob. High-affinity binding of the 
fibre knob to its receptors is the first step for adenoviral infection. The attachment of 
adenoviruses to the cells is reviewed in more depth elsewhere (e.g. [4, 5]). Other parts of the 
capsid apart from the fibre knob, like the fibre shaft and the hexon proteins are also important 
for binding, especially in vivo after intravascular administration. Attachment of blood factors 
(like clotting factor X) to the hexon proteins or the fibre shaft can modify the biodistribution 
of the virus in vivo (e.g. [6-9]).  However, the focus of this project is on modifications of the 
fibre protein. 
2) Internalisation of the virus by receptor-mediated endocytosis. After binding of the fibre 
knob to its receptor, RGD motifs on the penton base will bind to integrins and induce 
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internalisation of the virus (Figure 1B), although internalisation is still possible even with 
RGD-deficient viruses [4, 10]. 
Figure 1; The viral capsid and the interactions with the viral receptors 
 
 
(A) Illustration of the adenoviral capsid. The main component of the capsid is the hexon protein (blue). The 
penton bases (yellow) and the fibres (green) are located at the 12 vertices of the icosahedron. The fibre knob 
and shaft are shown. The fibre tail is not seen in this illustration. The fibre tail is the part of the fibre that 
interacts with the penton base. This illustration was taken from  Zhang and Bergelson (2005) [4].  (B) A model 
of Ad5 capsid interactions with its receptors. The hexons are blue, the penton base yellow, and the fibre protein 
green. Flexibility of the fibre shaft is required to allow binding of the penton base RGD motif to integrins. 
Illustration taken from Wu et al. (2003) [11]. 
A 
B 
CAR 
Fibre knob 
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Figure 2; Intracellular trafficking of adenovirus serotype 5 
 
The figure was taken from Leopold and Crystal (2007) [12]. 
3) The virus will then have to escape the endosomes, traffic to the nucleus and import its 
genome into the nucleus (Figure 2). The intracellular trafficking of adenoviruses is 
reviewed by Leopold and Crystal (2007) [12]. The fibre protein plays an important role in 
intracellular trafficking, therefore modifying the fibre will also affect the intracellular 
pathway followed by the virus. For example, replacing the fibre knob of adenovirus serotype 
5 with the fibre knob of adenovirus serotype 35 results in retention of the virus particles in 
the endosomal/lysosomal compartment for a longer period and the virus uses the lysosomes 
to achieve perinuclear localization [12, 13]. 
4) Adenovirus transcription (early phase) and replication (e.g. [14, 15]). The early phase 
transcription products are important to create an optimal intracellular environment for viral 
transcription and replication. Early region 1 (E1) is the first region to be transcribed and is 
essential for the adenoviral life cycle. Briefly, the E1A unit activates transcription and 
induces the host cell to enter the S phase, while E1B unit products block apoptosis (by 
binding and inactivating p53). An important interaction of E1A proteins, is binding to 
retinoblastoma protein (pRB) which results in release of E2F transcription factor and 
therefore induction of S-phase entry. Adenoviruses that have E1 region deletions or lack 
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expression of E1 region products (e.g. with tumour-specific promoters) are replication 
deficient. The early region 3 (E3) is not essential for the virus cycle, therefore transgenes are 
commonly inserted in place of E3 region genes. However, products of the E3 region protect 
the virus from the immune system in vivo, while the adenovirus death protein (ADP, E3 
11.6K) is important for cytolysis and virus progeny release. Therefore, maintaining 
expression of E3 region genes after insertion of the transgene (e.g. [16]) is sometimes 
desirable. 
5) Adenovirus transcription (late phase) and packaging (e.g. [14], [15], [17]). During late 
transcription, structural proteins are expressed and transported to the nucleus where the viral 
genome is packaged and new virus particles are formed. 
6) Cell death and adenovirus release. As discussed above ADP is important for this process, 
therefore maintaining its expression after insertion of a transgene in the E3 region is desirable 
for oncolytic virotherapy. It is worth noting that the cell death induced by oncolytic 
adenoviruses is different from the classical apoptosis. Oncolytic adenoviruses can induce 
autophagy (e.g. [18]) or other immunogenic types of cell death which is essential for 
induction of anti-tumour immunity. The role of immunogenic cell death in oncolytic 
virotherapy is reviewed elsewhere (e.g. [19]). 
There are many ways to achieve tumour selectivity of adenoviruses, the most popular being genetic 
engineering at the transductional (e.g. [20]) or transcriptional level (e.g. [21]). At the transductional 
level, modifications of the viral capsid have the potential to improve both the transduction efficacy 
and the specificity of the virus. The focus of this project is on adenoviruses with modified fibres, but 
other capsid modification are also possible (e.g. [20]). At the transcriptional level, tumour specificity 
can be achieved with tumour-specific promoter control of essential viral genes (like E1 region genes 
in the case of adenoviruses). 
Considering the many choices available it was reasonable to start with a side-by-side comparison in 
vitro in liver cancer cell lines and more importantly in primary human hepatocytes. Here, four fibre-
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modified and a wild-type fibre adenovirus were constructed to compare their transduction efficacy 
and specificity. Furthermore, three replication-selective viruses, constructed in a parallel project [22], 
were compared for their selectivity and cytotoxicity. See page 12 and Table 1 for a description and 
the naming of the viruses used.  
As explained above, the adenovirus fibre is important for binding of the virus to the cell surface, the 
first step for adenoviral transduction. The rationale for the fibre modifications is that CAR 
(coxsackievirus and adenovirus receptor), the receptor for the adenovirus serotype 5 (Ad5), has been 
reported to be commonly downregulated in many cancers, including hepatocellular carcinoma [23, 
24], therefore limiting the usefulness of the wild type virus. Retargeting the virus to other receptors 
by modifying the adenovirus fibre can overcome this problem, and potentially increase both the 
selectivity and transduction efficacy of the virus. The fibre-modifications compared here include;  
 a chimeric adenovirus serotype 5/ serotype 3 fibre that uses DSG2 (desmoglein 2) as a 
receptor [25, 26],  
 a chimeric adenovirus serotype 5/ serotype 35 fibre that binds to CD46 [27],  
 an Ad5 fibre with an RGD motif insertion that binds to integrins like αvβ3 and αvβ5[28], and  
 an Ad5 fibre with a peptide motif insertion that binds to integrin αvβ6 [29].  
All have been reported to increase the transduction efficacy of the virus especially in cell lines 
with low or no expression of CAR. However improved transduction efficacy has been shown 
even for cells positive for CAR (e.g. for Ad5/RGD [28, 30], for Ad5/FMD [29] and for Ad5/35 
[23]). Furthermore, some of these modification might result in better tumour-specificity. For 
example, CD46 has been reported to be overexpressed in HCC compared to normal liver [23, 31], 
while the integrin αvβ6 has been reported to be a very specific marker for cholangiocarcinoma 
[32].  
Tumour selectivity of the conditionally-replicating viruses used here is achieved with tumour-specific 
promoter control of the viral E1A gene and/or the Δ24 deletion of the E1A gene. This deletion 
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ablates binding of E1A to pRB (retinoblastoma protein) therefore allowing viral replication only in 
cancer cells which have disrupted RB function [33]. One virus has just the Δ24 deletion. The other 
combines the Δ24 deletion with E2F-controlled E1A expression [34]. In the last virus, E1A 
expression is controlled by the hTERT (human telomerase reverse transcriptase) promoter [35]. Both 
promoters are highly active in cancer cells but not in normal tissues, and all three viruses have 
demonstrated specificity for tumour cells and cytotoxicity at least as good as that of the wild-type 
virus, while sparing the normal cells (e.g. [33-35]). 
Oncolytic adenoviruses have been used in clinical trials with remarkably low toxicity even after 
intravascular or intrahepatic administration (e.g. [36-43]). However, the first generation of oncolytic 
adenoviruses were ineffective, at least when used as a single agent [36]. Onyx-015 is an example of 
the first generation oncolytic adenoviruses and features a deletion of E1B-55kd, which among other 
functions binds and inactivates p53, and a partial E3 region deletion. However, these deletions result 
in a significantly attenuated virus [36]. Newer generations of replication-selective viruses, e.g. those 
with tumour-specific promoters, achieve tumour specificity without loss of important viral genes, and 
therefore maintain cytotoxicity at least comparable to that of the wild type virus.  Examples of newer 
oncolytic adenoviruses that have been used in clinical trials include; 
1) Telomelysin: It is an Ad5 virus, with an RGD motif insertion in the fibre and is the first 
replication competent virus with a fully functional E3 region. To achieve tumour specificity 
the E1A region is controlled by the hTERT promoter and E1B is linked with an IRES. 
Telomelysin has been used intratumourally in a phase I clinical trial for patients with a 
variety of solid tumours [38]. 
2) ICOVIR-7: Briefly, tumour selectivity is achieved with a modified E2F promoter to control 
E1A and the Δ24 deletion. ICOVIR-7 is also based on Ad5 and has an Ad5/RGD fibre to 
enhance tumour transduction. It has been used in patients with advanced and progressive 
solid tumours [37].  
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3) Ad3-hTERT-E1A: This serotype 3, hTERT-controlled adenovirus has been used 
intratumourally/intravenously in patients with progressive advanced solid tumours [42]. 
4) Ad5-Δ24-GMCSF: A Δ24 deleted Ad5 virus expressing the immunostimulatory molecule 
GM-CSF. It has been used to treat patients with advanced solid tumours [43].  A similar virus 
with an Ad5/3 chimeric fibre has also been used intratumourally and intravenously in 
combination with cyclophosphamide [39].  
Briefly, all the above-mentioned viruses had encouragingly low toxicity in the relevant clinical 
studies and demonstrated evidence of anti-tumour activity. Anti-tumour responses included 
mainly stabilisation of the disease, a few partial responses and rarely complete responses. Only 
one phase III trial has been completed so far (in China) [44]. Oncorine, an oncolytic adenovirus 
similar to Onyx-015, resulted in increased response rates in combination with chemotherapy and 
received approval by China’s SFDA.  
To further increase the anti-tumour efficacy, there is now more focus on combining oncolytic 
virotherapy with other treatments, or arming the viruses with therapeutic transgenes. More 
importantly the immunotherapeutic potential of oncolytic viruses has been realised (e.g.[45]) and 
oncolytic viruses are commonly engineered to express immunostimulatory molecules, like  GM-CSF 
or CD40-ligand. CD40-ligand (CD40L) is a co-stimulatory molecule. Its receptor (CD40) belongs to 
the TNF receptor superfamily and is expressed by antigen presenting cells, like dendritic cells, 
macrophages and B-cells. CD40-CD40L interactions are important for the crosstalk among dendritic 
cells, T-cells and B-cells (reviewed in reference [46]) and expression of CD40L intratumourally by 
adenoviruses can overcome the immunosuppressive tumour microenvironment by shifting the T-cell 
response from Th2 to Th1 ([47, 48]). Furthermore, CD40L can induce apoptosis in some cancer cell 
lines that are expressing CD40 (e.g. [49]) and many cancers including HCC have been reported to 
express CD40 (e.g. [50]). In summary, oncolytic viruses expressing CD40L can have multiple 
therapeutic mechanisms [49]: (1) oncolysis, (2) direct anti-tumour effect by CD40L and (3) induction 
of anti-tumour immunity by both the CD40L and the virus-induced immunogenic cell death. A 
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CD40L-expressing virus, with an Ad5/3 chimeric fibre and hTERT control of E1A, has been safely 
used in cancer patients [48]. Furthermore, induction of antitumour immunity was demonstrated and 
there was some evidence of therapeutic efficacy (e.g. disease control at 3 months and improved 
survival compared to a historical control). Interestingly, response was seen in both injected and 
uninjected lesions, supporting a systemic, possibly immune-mediated, antitumour effect. 
Moreover, it has been reported that membrane-presented CD40 agonists are more effective at 
inducing cell death compared to soluble CD40L (e.g.[51]). CD40L can be cleaved from the 
membrane by matrix metalloproteinases and metalloproteinase inhibitors have been shown to 
enhance the cytotoxicity of a CD40L-expressing adenovirus [52]. Therefore, a mutated CD40L 
resistant to cleavage has been generated and has been shown to have a more potent antitumour effect 
[52].  
Here, two replication-defective (E1 and E3 deleted) adenoviruses expressing the wild type or the non-
cleavable CD40L were compared either alone or in combination with one of the replication 
competent viruses. The viruses were tested in vitro in HCC cell lines to test whether CD40L 
expression can have any direct cytotoxic effect. The above-mentioned immunostimulatory functions 
of CD40L were not studied in this project. 
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1) Side-by-side comparison of the fibre-modified viruses for their transduction efficacy and 
selectivity using established liver cancer cell lines, primary tumour cells and freshly isolated 
primary hepatocytes. An ideal virus would show high transduction of tumour cells and low 
transduction of primary hepatocytes. 
2) Side-by-side comparison of the replication-selective viruses for their tumour-specificity and 
oncolytic potency. An ideal virus would have low toxicity against primary hepatocyte but 
maintain oncolytic potency against tumour cells. 
3) Effect of CD40 ligand-expressing viruses on cell viability of HCC (hepatocellular carcinoma) 
cell lines and comparison of the wild-type CD40-ligand versus the non-cleavable version of 
the CD40-ligand. 
4) Study of the level of expression of the different viral receptors and CD40 using 
immunohistochemistry of formalin-fixed paraffin-embedded sections of liver tumours and 
surrounding non-tumour liver. The ideal scenario would be overexpression of the viral 
receptor and CD40 by tumours, and no or low expression by non-tumour tissues. 
5) The long-term goal is to insert the best fibre, and potentially the CD40L, into the best 
replication-competent vector, and eventually use this virus to treat HCC patients. 
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Making the constructs- propagation and quantification of the viruses 
Bacterial strain and cell lines 
For recombineering and preparation of the plasmid constructs the SW102 (E. coli) strain was used 
[53]. SW102 is readily transformable by electroporation due to its DH10B origin [54] and harbours 
the phage lambda-derived Red recombination system [55]. Expression of the recombination genes is 
controlled by a temperature-sensitive repressor and can be switched on at 42oC and off at 32oC. The 
lambda red recombination system is very efficient even with DNA homologies as short as 30-50bp. 
For the transfection experiments and for propagation of the viral constructs HEK 293 cells were used 
[56]. 293 cells were grown in DMEM (e.g. Gibco, 41965-039) supplemented with 10% fetal calf 
serum (FCS), 2mM L-glutamine (1:100 from Gibco, 25030-081) and penicillin/streptomycin (1:100 
from 100x stock, Gibco). For transfection/infection experiments DMEM with the HEPES 
modification (Sigma Aldrich, D6171) supplemented with 2% FCS and 
glutamine/penicillin/streptomycin (GPS) was used. 
Plasmids and viruses  
pPS1215A6(EGFP) (provided by Dr Peter Searle): Originating from vector pUC18, this plasmid 
contains an EGFP (enhanced green fluorescent protein) expressing cassette flanked by the adenovirus 
serotype 5 (Ad5) genome (nucleotides 1 – 357 to the left of the cassette and nucleotides 3525-10593 
to the right of the cassette. Nucleotide numbers are according to the Ad5 sequence from the National 
Center for Biotechnology Information GenBank, accession no. M73260/M29978). The EGFP coding 
region is from Clontech’s pEGFP1. Expression is driven by the immediate early cytomegalovirus 
promoter (CMV). The EGFP coding region is followed by DNA containing the second intron of the 
human beta-globin gene (to provide splice signals), and poly-A/ transcription termination signals 
from human complement C2 gene. 
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pAdZ5-CV5-E3+ : The AdZ adenovirus cloning system was described by Stanton et al [57]. Briefly, 
pAdZ5-CV5-E3+ is a single copy plasmid vector of the whole Adenovirus 5 genome with the E1 
region (nucleotides 478-3519) replaced by a selection cassette [ampr(ampicillin resistance)/lacZα (β-
galactosidase)/sacB (sucrose sensitivity)]. This cassette allows both positive (resistance to ampicillin 
and formation of blue colonies) and negative (resistance to 5% sucrose and formation of white 
colonies) selection. The plasmid also confers resistance to chloramphenicol. The sequence of the 
vector is available online: http://adz.cf.ac.uk/content/vector-maps (last accessed 15-04-2014). 
pPS1399N1 rightward (provided by Dr Peter Searle): This vector contains the ampr/lacZ/sacB 
cassette flanked by the Ad5 fibre N-terminus to the left (nucleotides 29511-31997) and part of the E4 
region to the right (nucleotides 32826-33599). 
pNKfiberRGD (provided by Ramon Allemany): This plasmid harbours the Ad5 fibre and flanking 
regions (from Not to KpnI sites), with the RGD-4C motif (peptide CDCRGDCFC) inserted in the HI 
loop of the fibre knob as described by Dmitriev et al [28].  
vAd5/3-hTERT-CD40L (provided by Oncos Therapeutics): Described by Diaconou et al [49], this 
Ad5 virus contains a chimeric adenovirus type 5/type 3 fibre, with the Ad5 knob domain being 
replaced by the Ad3 knob domain. Tumour specific replication is achieved by hTERT (human 
telomerase reverse transcriptase) promoter-controlled E1A expression. The CD40L gene is inserted 
in the E3 region. 
vAd5-A20FMDV2 (provided by Lynda Coughlan): In this Ad5 virus the wild type fibre is modified 
by insertion of a 20 amino acid peptide (derived from the foot-and-mouth disease virus) in the HI 
loop of the fibre knob, as described by Coughlan et al [29]. 
vAd5GFP-F35 (provided by Prof. Eric Blair): This Ad5 virus (described by Shayakhmetov et al 
[27]) contains a chimeric Ad5-35 fibre. Briefly, the adenovirus type 5 fibre tail (amino acids 1-44) 
was joined to the adenovirus type 35 shaft and knob domain. 
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Final viruses: See Table 1 for the naming of the viruses and a short description. The construction of 
the fibre-modified viruses is explained later. The fibres of these viruses are described in the relevant 
papers (Ad5/3 [58], Ad5/RGD [28], Ad5/FMD [29], Ad5/35 [27]). Briefly, the Ad5/3 fibre consists 
of the Ad5 fibre tail and shaft and the adenovirus serotype 3 fibre knob, and uses DSG2 (desmoglein 
2) as a receptor [26]. Ad5/RGD has an RGD peptide motif inserted in the HI loop of the fibre, which 
allows binding to several integrins (e.g. αvβ3 and αvβ5). Ad5/FMD has a peptide derived from the 
foot-mouth-disease virus inserted in the HI loop, which allows binding to αvβ6 integrin [29]. 
Ad5/RGD and Ad5/FMD also maintain binding to CAR. Ad5/35 fibre consists of the Ad5 fibre tail 
and the Ad35 fibre shaft and knob domains, and uses CD46 as a receptor [27]. All are replication 
defective (E1-deleted) and express EGFP. 
The replication-selective viruses [vAd5wt(hTERTp-E1A), vAd5wt(WTp-Ε1AΔ24), vAd5wt(E2Fp-
E1AΔ24)] were constructed and provided by Yi Hsuan Chen and are described in more detail in her 
thesis [22]. All have the EGFP gene inserted in the E3 6.7K/gp19 K region similar to ONYX-304 in 
reference [16]. Insertion in this site isn’t expected to affect the expression of neighbouring E3 genes 
[16]. The selectivity of the viruses is achieved by controlling the E1A transcription unit*1 with 
tumour-specific promoters and/or the Δ24 deletion in the E1A region. vAd5wt(WTp-E1AΔ24) only 
has the Δ24 deletion which ablates binding of E1A to pRB (retinoblastoma protein) (e.g. [33]). 
vAd5wt(E2Fp-E1AΔ24) combines the Δ24 deletion with tumour-specific control of the E1A gene 
[34]. Briefly, four E2F palindromic sites and one SP-I binding site were inserted to control E1AΔ24. 
In normal cells, binding of E2F-pRB complexes to the E2F palindromes inhibits E1A transcription. 
Therefore, viral replication can only occur in cancer cells with deregulated pRB/p16 pathway. 
Furthermore, this modification seems to enhance the antitumour activity of the virus compared to the 
virus with the wild type regulation of E1A [34].  In vAd5wt(hTERTp-E1A) the E1A is controlled by 
                                                     
*1 Early region 1A (E1A) is the first region to be transcribed after adenoviral infection and is necessary to 
create the appropriate intracellular environment for adenoviral transcription and replication. 
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the hTERT (human telomerase reverse transcriptase) promoter (e.g. [35]). The rest of their genome is 
the wild type Ad5 genome. 
The CD40L viruses were propagated from a pAdZ-based (pAdZ-CV5 [59]) plasmid vector. The 
plasmid vectors of the CD40L viruses were constructed and provided by Dr Searle. These viruses are 
E1/E3 deleted due to their pAdZ-CV5 origin. They contain the CD40L expressing cassette in place of 
the E1 region and expression is driven by the CMV promoter. The non-cleavable version of the 
CD40L is resistant to cleavage by matrix metalloproteinases and has been described previously [52]. 
Table 1; Naming of the viruses used and short description (see text for more details and references) 
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vAd5wt(EGFP) Virus with the wild type Ad5 
capsid 
All are replication defective 
(due to lack of the E1 region). 
All are expressing EGFP under 
the CMV promoter. 
vAd5/3(EGFP) Virus with an Ad5/3 chimeric 
fibre 
vAd5/RGD(EGFP) Virus with the Ad5/RGD fibre 
vAd5/FMD(EGFP) Virus with the Ad5/FMD fibre 
vAd5/35(EGFP) Virus with the Ad5/35 fibre 
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vAd5wt(hTERTp-E1A) E1A driven by the hTERT 
promoter 
All have the wild type Ad5 
capsid. All are expressing 
EGFP (inserted in the E3 
6.7K/gp19 K region). 
vAd5wt(WTp-E1AΔ24) E1A containing the Δ24 
deletion, driven by the wild 
type promoter 
vAd5wt(E2Fp-
E1AΔ24) 
E1A containing the Δ24 
deletion, and controlled by E2F 
C
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vAd5wt(wtCD40L) Virus expressing the wild type 
CD40-ligand 
Both have the wild type Ad5 
capsid. Both are E1/E3 deleted.  
Both are replication defective. 
They are not expressing EGFP. 
CD40-ligand is expressed under 
the CMV promoter 
vAd5wt(ncCD40L) Virus expressing the non-
cleavable CD40-ligand 
vAd5wt(E1AΔ24)(no EGFP) Replicating virus not expressing EGFP. Used for the co-infection 
experiments. 
 
DNA fragments for recombineering 
The DNA fragments (Table 2) were prepared by restriction digestion of the aforementioned plasmids 
and viruses. The digests were stained with SYBR gold (Invitrogen) followed by preparative gel 
electrophoresis [1% Agarose Ultrapure-Invitrogen, in Tris(40mM)-acetate(20mM)-EDTA 
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buffer(1mM)]. Bands were visualized on a blue light transilluminator and DNA from the relevant 
band was extracted with the QIAquick Gel Extraction Kit. 
Table 2; Description and origin of the fragments used for recombineering 
Fragments Description 
F1(sCMV) 2189 base pairs. From SacI (Roche) digestion of pPS1215A6(EGFP). 
Fragment contains the EGFP gene. The left end (=the last 83 base pairs of 
the CMV promoter) is homologous to the CMV promoter in the 
ampr/lacZ/sacB cassette. The right end is homologous to the Ad5 genome to 
the right of the cassette in pAdZ5-CV5-E3+ (See “construction of plasmid 
constructs” page 28 and Supplementary figure 3).  
F(cassette-in-
fibre) 
Provided by Dr Peter Searle. 5727 base pairs. From AgeI+PmlI (NEB) 
digestion of pPS1399N1. Fragment contains the ampr/lacZ/sacB cassette 
flanked by the Ad5 fibre N-terminus (nt 31042-31996*) to the left and part 
of the Ad5 E4 region to the right (nt 32826-33489*). See p. 28 and 
Supplementary figure 4. 
Ad5/3 
(NdeI-SspI)* 
2362 base pairs. From NdeI-SspI (Roche) digestion of Ad5/3-hTERT-
CD40L. Fragment containing the Ad5/3 chimeric fibre (from NdeI site in 
fibre tail to SspI site in the E4 region). 
Ad5/RGD 
(AgeI-PmlI)* 
2414 base pairs. From AgeI-PmlI (NEB) digestion of pNKfiberRGD. 
Fragment containing the Ad5/RGD fibre (from NdeI site in fibre tail to PmlI 
site in the E4 region). 
Ad5/FMD 
(NdeI-AvrII)* 
4442 base pairs. From NdeI-AvrII digestion of vAd5-A20FMDV2. 
Fragment containing the Ad5/FMD fibre (from NdeI site in fibre tail to 
AvrII site in the E4 region). 
Ad5/35 
(NdeI)* 
4094 base pairs. From NdeI digestion of vAd5GFP-F35. Fragment of 
Ad5/35 chimeric fibre (from NdeI site in fibre tail to the end of the virus).  
* according to Genbank M73260/M29978. 
 
Preparation of electrocompetent bacteria, electroporation and recombineering 
Competent SW102 bacteria were prepared as described by Stanton et al [57] (also available at 
http://adz.cf.ac.uk/files/AdZ-Protocol-2.pdf). Bacteria were grown overnight at 32oC in 5ml Veg LB 
medium (Fluka, 28713) with appropriate antibiotics (chloramphenicol 12.5 μg/ml ± ampicillin 
50μg/ml). 1ml of the overnight cultures was inoculated into 50ml Veg LB with appropriate 
antibiotics and incubated in a shaking incubator at 32oC for about 3-4 hours (ideally to an OD600=0.4- 
0.6). Expression of the lambda Red recombination proteins was then induced by incubating in a 42oC 
water bath for 15 minutes. Samples were then cooled on ice for 15 minutes. Cells were pelleted at 
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3750 rpm, 5 minutes, 0oC (Beckman GS 6R Centrifuge, GH-3.8 rotor) and washed twice in 40ml of 
ice-cold ddH2O. The pellet was resuspended in the volume left in the tube (approximately 400μl) 
after pouring off the supernatant. Aliquots of 25μl were mixed with 3μl of the DNA fragments (at 
least 10ng of DNA) and samples were electroporated (0.2 cm cuvettes, 2.5 kV- MicroPulser 
Electroporator, Biorad). Cells were recovered in 1ml Veg LB (no antibiotics) for 1 hour for positive 
selection, or in 5ml Veg LB (no antibiotics) for 4-5 hours for negative selection (to allow time for 
loss of sacB mRNA and proteins). Bacteria were then plated (30-100μl per plate aiming for well-
spaced colonies) onto selective plates (see next paragraph) and incubated at 32oC for 30-48 hours 
(bacteria grow slower at 32oC and it takes some time for the blue colour to develop). 
Selective plates 
SCIX plates; For negative selection (replacement of the ampr/lacZ/sacB cassette): 10g/L tryptone 
(Fluka, 95039), 5g/L yeast extract (Fisher Scientific, 10697612), 5% sucrose, 1.5% agar, 12.5 μg/ml 
chloramphenicol, 80μg/ml X-gal and 200μM IPTG. In the absence of salt, sucrose 5% can inhibit 
growth of E. Coli expressing sacB. Correct colonies should be white and sensitive to ampicillin. 
Sensitivity to ampicillin can be confirmed by restreaking the selected white colonies on ampicillin 
plates (SOB agar + ampicillin 50μg/ml). Therefore bacteria that still have the cassette cannot grow. 
Spontaneous loss of sacB function can also occur, without loss of the cassette, due to mutations. 
However, such bacteria will form blue colonies (provided that lacZ gene is still functional) (e.g. 
Figure 6A). 
CAIX plates; For positive selection (insertion of the ampr/lacZ/sacB cassette): SOB Agar, 12.5 
μg/ml chloramphenicol, 50μg/ml ampicillin, 80μg/ml X-gal and 200μM IPTG. Correct colonies 
should be blue (Figure 6B). 
Colonies that looked correct were then mini-prepped and confirmed with appropriate restriction 
enzyme digestion (see next paragraph). 
  
 
16 
Confirmation and propagation of plasmids constructs 
Liquid cultures (typically 10ml) were grown from candidate colonies and the plasmid DNA was 
extracted with an alkaline-lysis method (see page 67 in “Supplementary methods”). The plasmid 
DNA was digested with appropriate restriction enzymes to confirm the expected band pattern. 
Confirmed bacterial stocks were expanded (typically 500ml) for higher yield preparation and the 
plasmid DNA was purified with caesium chloride-ethidium bromide gradient centrifugation (see page 
68 in “Supplementary methods”). The constructs were confirmed once again with restriction enzyme 
digestion. 
Propagation-quantification of the viruses 
The purified plasmids were transfected to 293 cells with a calcium phosphate method (see page 69 in 
“Supplementary methods”). The pAdZ vector contains an expression cassette of I-SceI, a restriction 
enzyme whose recognition site is an 18 base-pair-long sequence, and therefore extremely rare. The I-
SceI cutting sites are inserted at the ends of the adenoviral backbone of the pAdZ vector and 
expression of I-SceI is activated in eukaryotic cells. Therefore, after transfection in 293 cells the 
adenoviral backbone is released from the plasmid vector (Supplementary figure 3). Cells were 
harvested a few days later when enough cytopathic effect*2 was present, and the virus was released 
from the cells with 3 freeze (-80oC)- thaw (37oC) cycles and vigorous vortexing. Then more 293 cell 
cultures were infected for virus propagation and the virus was purified with caesium chloride density 
gradient centrifugation (see page 70 in “Supplementary methods”). The DNA concentration of the 
virus preps was measured with a fluorometric assay based on SYBR gold staining of the DNA (see 
page 71 in “supplementary methods”). The virus particle concentration was calculated based on the 
DNA concentration and the molecular weight of the adenoviral DNA. The replication-selective and 
the CD40L viruses were also titrated with the Adeno-X Rapid Titer Kit (Clontech) and the infectious 
units (IU) concentration of the virus preps was calculated. 
                                                     
*2 Cytopathic effect: rounding and detachment of the cells caused by the adenoviral infection. 
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Comparing the viruses 
Cell lines and primary cells 
To compare the viruses the following cell lines were used: two HCC-derived cell lines (HepG2 [60] 
and Huh7.5 [61]) and two ICCA (intrahepatic cholangiocarcinoma)-derived cell lines (CC-LP-I and 
CC-SW-I[62]). Cells were cultured in DMEM supplemented with 10% FCS, L-glutamine and 
penicillin/streptomycin. For the HCC cell lines the medium was also supplemented with non-
essential amino acids (Sigma-Aldrich, M7145).  
Primary tumour cells recently isolated (January 2014) by Dr E. Humphreys from an intrahepatic 
cholangiocarcinoma (ICCA) were also tested. The method used for their isolation and the culture 
medium are described in reference [63]. Fresh hepatocytes were isolated and provided by Dr E. 
Humphreys. One case was from a liver with cryptogenic cirrhosis and the other from a marginal liver 
donor. The method for isolation and the culture medium are described in reference [64]. 
Infection protocol 
For infections of the cell lines the medium was supplemented with 2% FCS (instead of the 10% FCS 
that was used for culture). For the primary tumour cells and hepatocytes the same medium as for 
culture was used. The viruses were diluted to appropriate doses in the infection medium. For the 
infection, the cell culture medium was removed and the virus containing medium was added. The 
absorption time3* used for infection was 40 minutes (at 37oC, 5%CO2), with gentle rocking of the 
plates at 20 minutes. The absorption volume4* used was 600μl, 300μl or 180μl for 6-well, 12-well or 
24-well plates respectively. The role of absorption time and volume, and rocking are discussed in 
                                                     
*3 Absorption time: The period of time for incubating the cells with the virus (from adding the virus to 
removing the virus-containing medium).  
*4 Absorption volume: The volume used for infection during the absorption time 
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detail by Mittereder et al [65]. A short absorption time was selected based on the assumption that this 
might increase the sensitivity for detecting any differences on the transduction efficacy of the fibre-
modified viruses. After the absorption time, the virus-containing medium was removed and the wells 
were washed once with PBS. Handling many wells simultaneously was avoided to prevent drying of 
the cells (Figure 3). 
Figure 3; No fluorescent cells in a dried area of the well  
 
 
Comparison of the fibre-modified viruses 
The infections were performed as described above. To compare the transduction-efficacy of the fibre-
modified viruses, cells were infected with the same multiplicity of infection (MOI; virus 
particles/cell) of each virus and the percentage of infected cells were determined with flow cytometry 
as described later (“Flow cytometry” section). The relative transduction efficacy was calculated as a 
percentage of the efficacy of the wild type virus: 
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑎𝑐𝑦 =
% of positive cells infected by the fibre modified virus
% of positive cells infected by vAd5wt(EGFP)
∗ 100  
i.e. the relative transduction efficacy of vAd5wt(EGFP) is 100% 
Dried area 
Healthy area 
Photo from fluorescence 
microscope;  
Three 6-well plates were handled at 
the same time. The medium was 
removed from all the wells before 
adding the virus. The delay resulted 
in drying of the last wells and the 
affected areas died. 
  
 19 
When the viruses were tested in duplicate/triplicate, the average % of positive cells was calculated for 
each fibre-modified virus and was divided with the average % of positive cells infected with the same 
MOI of vAd5wt(EGFP). This was done separately for each MOI tested and the total average for each 
experiment was calculated. Then results from independent experiments were averaged and 
summarised in a single bar chart (mean ± SD error bars). 
To determine the appropriate time for harvesting, a time course experiment was done with the HCC 
cell lines. Cells were harvested and fixed for flow cytometry at 3 different time points after infection; 
at about 30 hours, 40 hours and 48 hours. vAd5wt(EGFP) and vAd5/35(EGFP) were selected for the 
time course experiment because of their very different infection kinetics and intracellular trafficking 
(e.g. see reference [13]). 
Co-infection experiments 
The rationale for the co-infection experiments is explained in the relevant section in “RESULTS”. 
The co-infection experiments were done in HepG2 and Huh7.5. A replicating virus differing from the 
wild type Ad5 genome only at its Δ24 deletion in the E1A region [vAd5wt(WTp-E1AΔ24)(no-
EGFP)] was used to complement the replication-defective fibre-modified viruses. 2*10^5 cells were 
seeded in 24-well plates and infected the next day with 3*10^7 virus particles of the fibre-modified 
viruses. After washing the viruses the cultures were incubated for 2 more hours before infecting with 
the replicating virus. This was done to minimize any competition between the replication-defective 
and the replicating viruses. Cells were infected with 3*10^7 virus particles of the replicating virus. 
For both infections the absorption time was 40 minutes and the absorption volume 180μl. Cells were 
harvested and fixed for flow cytometry at 16 hours after infection with the replicating virus. This 
early time point was chosen to avoid the shift of the negative population observed at high levels of 
EGFP (see page 73 in “Supplementary material”). 
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Comparison of the replication-selective and CD40L-expressing viruses 
The cytotoxicity of the replication-selective and CD40L-expressing viruses was compared with MTT 
viability assays (see below). Furthermore, for the EGFP-expressing replication-selective viruses, the 
median fluorescence intensity of infected cells or the mean fluorescence intensity of the total 
population (including the uninfected population of the sample) were measured with flow cytometry to 
compare the replication efficiency of the viruses. The mean fluorescence intensity of the total 
population was used when a shift of the negative population (see page 73 in “Supplementary 
material”) was present therefore preventing the use of a uniform gating strategy to define the positive 
populations. 
 
MTT viability assays 
MTT assays were used to compare the cytotoxicity of the replication-selective and CD40L-
expressing adenoviruses. Cells were seeded in 96-well plates one day before infection. When 
possible, edge and corner wells were avoided, or excluded from analysis if a significant edge effect 
was observed (Figure 4). On the day of the infection (day 0) the medium was removed and the cells 
were infected with serial dilutions of each virus in 100μl of the infection medium per well (usually 
each dose in triplicate or duplicate wells). 100μl of fresh infection medium were added the same or 
next day and plates were incubated (37oC, 5% CO2) until analysis at different time points (e.g. day 3, 
day 5, day 7). For the MTT assay, MTT stock solution (5mg/ml in PBS, from MTT powder- Sigma 
Aldrich M5655) was diluted 1:10 in 10% FCS medium without phenol red (Gibco, 31053-028). The 
medium from the wells was gently removed with a syringe and needle (to minimize any disruption of 
the cell monolayer) and replaced with 100μl of the MTT-medium. A well with the medium and no 
cells was used as a “blank” control. The plates were then incubated (37oC, 5% CO2) for 2 hours 
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(HCC cell lines) or 4 hours (primary hepatocytes). After the incubation time, 80μl*5 of the MTT-
medium were carefully removed and 100μl of DMSO (Sigma-Aldrich, D5879) were added per well 
to dissolve the dye. The plates were placed on a microplate shaker and analyzed within an hour with 
the Wallac 1420 VICTOR2 plate reader. Absorbance was measured at a wavelength of 550nm 
(Huh7.5 and primary hepatocytes), or at 490nm (HepG2; absorbance was saturated at 550nm). The 
corrected absorbance or the percentage viability were calculated as shown below: 
Corrected absorbance = (measured absorbance)– (absorbance of the blank) 
 
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
average corrected absorbance of infected wells
 average corrected absorbance of uninfected wells
∗ 100% 
Figure 4; Edge effect in a seven-day-old 96-well pate for MTT assay 
 
Note the higher pH (as indicated by the colour of the pH indicator- phenol red) of the edge wells and, 
to a greater extent, of the corner well. Although not obvious in this photo, the volume of the medium 
was much lower in the corner and edge wells due to the higher evaporation rate of these wells (see 
also references [66, 67]). 
 
                                                     
*5 A variable amount of formazan crystals is lost during aspiration of the MTT medium, especially from wells 
infected with higher MOI. This might compromise comparisons between the viruses. It was noted that most of 
the crystals are lost during aspiration of the final μl of the MTT medium. Therefore, to minimize any variability 
due to aspiration of formazan crystals, I avoided aspirating the whole 100μl of the MTT-medium. 
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Flow cytometry 
Harvesting-fixation of cells:                                                                                                              
Cells were harvested with TrypLE-Express (Life Technologies). Trypsin was then inactivated with 
equal amount of 10% FCS medium and cells were washed in PBS. Cells were resuspended in 2% 
PFA (paraformaldehyde) and placed on ice for 20 minutes. Cells were then pelleted, the supernatant 
removed and then washed with 100μl PBS. Cells were resuspended in 100μl PBS +10% FCS and 
stored in the fridge until analysis by flow cytometry (usually the same or next day). 
Flow cytometry settings, gating and analysis:                                                                                                                                             
Cells were diluted in a total of 500μl PBS to about 1-5 million cells/ml. Samples were run on Cyan 
ADP Analyzer and analyzed with “Summit V4.3” software. An example of the settings and gating 
strategy is given in Figure 5. Events were gated to exclude debris and clumped cells (region R1 from 
“FS Lin vs SS Lin” histogram and region R2 from “FS Lin- pulse width” histogram). FITC voltage 
setting was adjusted so that the negative population is placed within the first decade of the 
logarithmic FITC histogram. Gating for the positive population (region R3, FITC-log vs event count 
histogram) was based on uninfected control samples. When there was very little overlap between the 
positive and negative distributions, the gate was set so that less than 1% of the negative control 
population is positive. When the overlap was significant, the gate was set so that about 2-5% of the 
negative control sample is positive, depending on the extent of the overlap. The same gating strategy 
was used for all samples for each independent experiment. 
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Figure 5; An example of the gating strategy used in flow cytometry 
 
 
 
 
Antibodies 
See Table 3 below 
Table 3; Antibodies used for immunohistochemistry, flow cytometry and blocking 
experiments 
Antibodies 
Concentration/dilution used for 
IHC* Flow cytometry Blocking experiments 
Mouse IgG1 isotype control 
(Molecular Probes, MG100- 
0.1mg/ml)  
2 μg/ml 
(1:50)** 
10 μg/ml (1:10) NA 
Rabbit Ig fraction isotype control 
(Dako, X0903)  
2 μg/ml** 2 μg/ml NA 
SS; side scatter, FS; forward scatter Lin; linear, Log; logarithmic, 
R1,R2,R3; regions for gating 
Gated for R1 
Gated for R1 and R2 
R3; positive population region 
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Goat isotype control (Southern 
Biotech, 0109-01, 5mg/ml) 
2 μg/ml** NA NA 
Rabbit anti-ITGAV* (Sigma-Aldrich 
HPA004856- 0.1mg/ml) 
1 μg/ml 
(1:100) 
NA NA 
Rabbit anti-ITGB8* (Sigma-Aldrich 
HPA027797- 0.1mg/ml) 
5 μg/ml 
(1:20) 
5 μg/ml (1:20) NA 
Rabbit anti-ITGB5 (Thermo 
Scientific, PA1-37931) 
1:20 1:20 or undiluted NA 
Mouse anti-CD61 (2f2 clone) (Thermo 
Scientific, MA5-11437) 
1:25-1:50 1:25 NA 
Rabbit anti ανβ6 (Biorbyt orb100289- 
0.5mg/ml) 
6.7 μg/ml 
(1:75) 
10 μg/ml (1:50) 10-20μg/ml 
Rabbit anti-CD46 (Biorbyt orb10329-
0.5mg/ml) 
10 μg/ml 
(1:50) 
10 μg/ml (1:50) 10 μg/ml (1:50) 
Rabbit anti-DSG2 (Sigma-Aldrich 
HPA004896- 0.3mg/ml) 
3 μg/ml 
(1:100) 
6 μg/ml (1:50)*** 10 to 30 μg/ml 
Rabbit anti-CAR (Sigma-Aldrich, 
HPA030412- 0.2mg/ml)  
2.7 μg/ml 
1:75 
NA 2 μg/ml*** 
Mouse anti-CD40, clone EA-5 
(Calbiochem, 217590, 1mg/ml) 
20μg/ml 
(1:50) 
20μg/ml (1:50) NA 
goat anti-CD154 (AbD Serotec, 
AHP1029-1mg/ml) 
1:50 – 
1:100 
NA NA 
Vector ImmPRESS HRP anti-goat, 
anti-mouse, anti-rabbit 
Undiluted NA NA 
Mouse anti-CAR clone RMCB (EMD 
Millipore, 06-644, 200μg) 
NA ~ 10 μg/ml (1:100) ~ 10 μg/ml (1:100) 
Mouse anti-CD46 clone MEM-258 
(AbD Serotec, MCA2113, 1mg/ml) 
NA 10 μg/ml (1:100) 10 μg/ml (1:100) 
Mouse anti- integrin aV, clone L230 
(Enzo Life Sciences, 100μg) 
NA ~ 10 μg/ml ~ 10 to 20 μg/ml (1:33) 
Mouse anti-DSG2, clone 6D8 (AbD 
Serotec, MCA2271, 0.5mg/ml) 
NA 10 μg/ml (1:50) 10 to 40 μg/ml (1:50) 
Rat anti- integrin αvβ6, clone 53a.2 
(Abcam, ab97588, 1.52mg/ml) 
NA 10 μg/ml **** 10 μg/ml 
Goat anti-mouse IgG1-FITC 
(SouthernBiotech, 1070-02) 
NA 1:250 NA 
Goat anti-rabbit Ig-FITC 
(SouthernBiotech, 4010-02) 
NA 1:250 NA 
* ITG AV/B8/B5; integrins αv, β8 and β5 respectively 
   IHC; immunohistochemistry 
** Ideally the concentration of the isotype controls should have been equal to the concentration of the 
primary antibodies 
*** Lower concentration compared to the rest antibodies (higher concentration would require a much 
higher volume of antibody) 
**** A secondary anti-rat IgG2a antibody was not available, so I tried the anti-mouse IgG1 as it was 
not crossed-absorbed against rat IgG 
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Immunohistochemistry (IHC) 
Formalin fixed-paraffin embedded sections from hepatocellular carcinomas and surrounding non-
tumour tissues were stained for the different viral receptors, CD40 and CD40L (CD154). Sections 
including both cancerous tissue and non-cancerous margin were preferred. This allows easier 
comparison of the levels of the studied antigens between the tumour and the surrounding liver. 
Sections were dewaxed and rehydrated in serial clearine and alcohol solutions. Endogenous 
peroxidase was blocked with 0.3% H2O2 in water for 15 minutes. For antigen retrieval a citrate low 
pH solution was used (Vector H-3300). The solution (10ml in 1L of dH2O) was heated in a 
microwave oven for 10 minutes. The slides were then placed in the solution in a plastic rack and were 
heated for 20 minutes in the microwave oven. After cooling (for 10 minutes at room temperature and 
then under running tap water), non-specific antibody binding was blocked with 2.5% horse serum 
(Vector) for 20 minutes. Primary antibodies diluted in the 2.5% horse serum were then added for 1 
hour at room temperature. Sections were then washed in BupH TBS (Thermo scientific) and the 
secondary ImPRESS peroxidase –conjugated antibodies (Vector) were added for 1 hour at room 
temperature. Slides were washed again in TBS for 5 minutes and then the substrate was added (DAB- 
Vector ; 1 drop per 1 ml diluent) for a few minutes. The slides were counter-stained in Mayers 
heamatoxylin for 4 minutes. Slides were then cleared and dehydrated (in serial alcohol and clearine 
solutions) and mounted with DPX. 
Note that I personally did this work for the first 4 tumours and the rest of IHC was continued by Will 
Marshall. However, I examined the sections and took the photos included here myself. 
Cell surface flow cytometry staining for the viral receptors and CD40 
Cells (HepG2, Huh7.5, CC-LP-I, CC-SW-I and primary ICCA ) were harvested with TrypLE 
Express (Gibco, 12605-010) and washed in PBS. Non-enzymatic harvesting with 10mM EDTA in 
PBS was also tried to exclude absence of staining due to trypsinization of the target antigens. 5*10^5 
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cells were incubated with the primary antibodies in 100 μl FACS buffer (PBS+10%FCS)*6 for 40 
minutes on ice. Cells were then pelleted by centrifugation and the supernatant was discarded. Cells 
were washed with 100μl PBS, and were resuspended in 100μl FACS buffer with the secondary FITC-
conjugated antibodies and incubated on ice for 40 minutes. 100μl PBS were added for washing, and 
cells were pelleted and resuspended in 100μl PBS and then transferred to FACS tubes with 400μl 
PBS for flow cytometry (Cyan ADP Analyzer- Summit v4.3). All samples were analyzed using the 
same PMT voltage setting for FITC (480V). The isotype-corrected median fluorescent intensity was 
used to compare the levels of expression of the target antigens among the different cell lines: 
𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑚𝑓𝑖 = (𝑡𝑜𝑡𝑎𝑙 𝑚𝑓𝑖 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒) − (𝑡𝑜𝑡𝑎𝑙 𝑚𝑓𝑖 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒)  
Where mfi refers to the median fluorescence intensity. 
Note that this method is only semi-quantitative and does not represent an accurate quantification of 
the antigen. Truly quantitative methods using calibration beads are available (e.g. [69]). For the 
antibodies and concentrations used see Table 3. Note that for the rat anti-αvβ6 (clone 53a.2, IgG2a), 
an appropriate isotype control and secondary antibody were not available. As a secondary antibody I 
used the anti-mouse IgG1 exploiting the species cross-reactivity. 
Blocking experiments 
To confirm the receptor specificity of the fibre-modified viruses, blocking experiments were 
performed. CC-LP-I and CC-SW-I cell lines were selected for the blocking experiments for reasons 
discussed later. For the antibodies and concentrations used see Table 3. The monoclonal antibodies 
used were selected based on a literature review to identify antibodies that have been used successfully 
for similar blocking experiments in the past (RMCB [27, 70, 71], MEM-258 [72, 73], L230 [27, 70], 
53a.2 [29]) . 2*10^5 cells were seeded in 24-well plates one day before the experiment. On the day of 
                                                     
*6 Retrospectively, and considering that recovering cell function was not an issue, sodium azide could have 
been added in the FACS buffer to further minimize surface antigen loss [68. Abcam. Indirect flow 
cytometry protocol.  [cited 2014 30/07]; Available from: http://www.abcam.com/protocols/indirect-flow-
cytometry-protocol.]. 
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the experiment, the medium was removed and cells were incubated with the relevant antibodies, 
diluted in the infection medium (2% FCS medium), for 1 hour in the cell culture incubator (37oC, 5% 
CO2). The virus was then added to the wells at an MOI of 10 vp/cell (for CC-LP-I) or 100 vp/cell (for 
CC-SW-I) and the plates were placed in the incubator for another hour. The medium was then 
removed, wells were washed twice with 0.5 ml PBS and fresh infection medium was added. Cells 
were harvested for flow cytometry 2 days later and the percentage transduction was calculated: 
                                                      % 𝑡𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =
=
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 𝑓𝑟𝑜𝑚 𝑤𝑒𝑙𝑙𝑠 𝑝𝑟𝑒𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑚𝐴𝑏
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 𝑓𝑟𝑜𝑚 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑤𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑚𝐴𝑏 𝑝𝑟𝑒𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛
  
The percentage of positive cells was averaged from duplicate wells for each antibody or control. 
mAb= monoclonal antibody 
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Construction of the plasmid vectors 
Plasmid vectors of the fibre-modified viruses were made in three recombineering steps: 
1) Insertion of the CMV-EGFP cassette in the left end of the adenoviral backbone of pAdZ5 (in 
place of the selection cassette) to allow monitoring of viral infection by fluorescence 
(Supplementary figure 3) 
2) Insertion of the ampr/lacZ/sacB cassette in the fibre region of the adenoviral backbone 
(allowing for selection of correct colonies after step 3) (Supplementary figure 4). 
3) Insertion of the modified fibres in place of the region with the cassette (Supplementary figure 
4). 
For the first step, competent SW102 E. coli transformed with pAdZ-CV5-E3+ were electroporated 
with the DNA fragment F1(sCMV) (Table 2). Recombineering results in an AdZ plasmid vector 
(named as pSK1A) of the wild type virus with an EGFP expressing cassette in place of the E1 region. 
Bacteria were spread on SCIX selective plates (Figure 6A) and selected white colonies were mini-
prepped and confirmed with HindIII digestion (Figure 7A). Sensitivity to ampicillin of the selected 
colonies was also confirmed by restreaking the colonies on ampicillin plates (not shown). 
For the second step (Supplementary figure 4), competent SW102 harbouring pSK1A2 (= pSK1A 
from colony no 2) were electroporated with the DNA fragment F(cassette-in-fibre) (Table 2), 
resulting in a plasmid vector (named as pSK2A2) with the ampr/lacZ/sacB selection cassette in the 
fibre region of the adenoviral backbone. Bacteria were inoculated on CAIX selective plates (Figure 
6B) and selected blue colonies were mini-prepped and confirmed with BamHI digestion (Figure 
7B). 
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For the third step (Supplementary figure 4), competent SW102 harbouring pSK1A2 were 
electroporated with the modified-fibre fragments (Table 2) resulting in plasmid vectors similar to 
pSK1A but with the modified fibres. Bacteria were plated on SCIX plates (not shown) and selected 
white colonies were mini-prepped and confirmed with BamHI digestion and fibre-specific enzymes 
(results from digestions are not included, but the expected band pattern was confirmed). 
 
 
Figure 6; Selective plates for negative and positive selection 
 
 (A) SCIX plate inoculated with SW102-pAdZ5-CV5-E3+ electroporated with the DNA fragment F1(sCMV). White 
colonies should harbour the recombined plasmid (pSK1A). Blue colonies represent colonies with spontaneous loss of SacB 
functionality. The blue colour is retained due to the presence of the lacZ gene. (B) CAIX plate inoculated with SW102-
pSK1A2 electroporated with the DNA fragment F(cassette-in-fibre). Blue colonies should harbour the recombined plasmid 
(pSK2A2). 
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Figure 7; HindIII and BamHI digestion of minipreps 
                                                                              
 
Propagation of the viruses from the plasmid vectors 
Plasmid vectors of the wild type and fibre-modified viruses from confirmed colonies were bulk 
prepped and purified with CsCl-EtBr gradient centrifugation (e.g. Figure 8A). The purified plasmids 
were then confirmed again by restriction enzyme digestion with BamHI and fibre-specific enzymes. 
Confirmed plasmids were transfected with a calcium phosphate-based method in HEK 293 cells 
where the adenoviral backbone was released due to the self-excision system of the AdZ vectors. 
Successful transfection was confirmed under a fluorescence microscope (e.g. Figure 8B). After a 
few days (waiting for the cytopathic effect to develop) the viruses were harvested and further 
propagated in HEK 293 cultures. Virus harvested from ten T150 flasks was purified with a caesium-
chloride density gradient method (e.g Figure 8C). DNA from a small aliquot was extracted and 
constructs were confirmed by restriction enzyme digestion. Enzymes with cutting sites in the 
modified parts of the fibre were preferred to further confirm the successful recombineering of the 
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modified fibres. DNA concentration of the virus preps was quantified with a SYBR Gold DNA assay 
and virus particles were calculated (Table 4). Several aliquots of each virus were then stored at -
80oC. These aliquots were used for subsequent experiments. This was done to avoid repeated freeze-
thawing of the virus prep as this can affect the infectivity of the viruses. 
Figure 8; Bulk prep (A), infected cells (B) and virus prep (C) 
   
(A) Photo of a CsCl-EtBr density gradient of a plasmid bulk prep. The arrow indicates the lower band 
representing supercoiled plasmid DNA. (B) Photo of a 293 culture infected with vAd5/FMD(EGFP). (C) Photo 
of banded vAd5/RGD with the CsCl density centrifugation method. 
 
Immunohistochemistry of HCC 
According to the so far stained sections none of the viral receptors seems to be specifically expressed 
by the tumour compared to the surrounding liver (Figure 10). Staining for integrins αv and β5 was 
consistently strongly positive in all tumour and non-tumour sections stained so far. CD61 (integrin 
β3) on the other hand was not detected in any of the sections. Integrin αvβ6, the receptor for the 
Ad5/FMD fibre, was rarely positive (2 of 8 tumours), which is similar to what previously reported 
[32]7. In the 2 tumours that were positive, the non-tumour margin was also stained positive (e.g. 
Figure 10). CAR was detected in most of the tumours stained so far (6 of 7) (Supplementary photo 
                                                     
*7 Although according to that study none of the HCCs (n=77) were positive. 
Empty virus 
Virus band 
A 
B 
C 
2ml CsCl 
1.45g/ml 
2ml 
Glycerol 
40% 
3ml CsCl 
1.32g/ml 
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1 and 2). In one case CAR expression was lost but alternative receptors were highly expressed 
(Figure 9). In sections with non-tumour margin available, CAR expression by the tumour was 
similar to that of the margin in 3 out 5 cases, and lower but present in the other 2 cases. In one section 
for which the corresponding non-tumour margin was not available, CAR expression was detected 
mostly focally. 
Table 4; Virus prep concentrations and enzymes used for confirmation of virus preps 
Virus IU/μl Virus particles/μl Confirmed by digestion with 
vAd5wt(EGFP) NA 2.77*109 HindIII 
vAd5/3(EGFP) NA 1.64*109 BglII, ScaI, (bulk prep also confirmed 
with BamHI) 
vAd5/RGD(EGFP) NA 3.25*109 SacII (bulk prep also confirmed with 
BamHI) 
vAd5/FMD(EGFP) NA 1.88*109 BstEII, KpnI, NdeI 
vAd5/35(EGFP) NA 3.08*109 AflIII, KpnI, NdeI, (bulk prep also 
confirmed with Asp718 and SpeI) 
vAd5wt(hTERTp-
E1A) 
2*10^7 2.75*108  
The replication selective viruses 
where made by Yi Hsuan Chen [22] vAd5wt(WTp-
E1AΔ24) 
3.18*107 2.66*108 
vAd5wt(E2Fp-
E1AΔ24) 
5.24*107 8.91*108 
vAd5wt(wtCD40L) 1.06*108 1.65*109 HindIII, EcoRV (bulk prep also 
confirmed with BglII) 
vAd5wt(ncCD40L) 9.3*107 2.57*109 HindIII, EcoRV (bulk prep also 
confirmed with BglII) 
Enzymes in bold indicate enzymes with cutting sites in the modified part of the fibre. 
Infectious units (IU) were calculated with the Adeno-X Rapid Titer Kit (clontech) in 293 cells 
The virus particles concentrations data for the three replication selective viruses were provided by 
Yi Hsuan Chen (the DNA concentration was converted to virus particles based on the conversion 
factor: 2.57*107 vp per 1 ng of DNA).  
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Finally, in the last section, CAR expression was concentrated mainly around the bile canaliculi, and 
therefore inaccessible to circulating adevovirus particles [74]. All but one tumours were positive for 
CD46 (10 of 11), but non-cancerous tissues were also positive in sections with available 
corresponding margin (5 of 5). In 2 of the positive sections CD46 was only detected focally*8.  DSG2 
was also consistently positive (10 of 10) but again the corresponding margin was also positive (5 of 
5).  CD40 was detected in most tumours stained so far (3/4), however the surrounding diseased liver 
was also found positive (Supplementary photo 3 and 4). Unexpectedly, most sections (both tumour 
and non-tumour) stained with the CD154 (CD40L) antibody were also strongly positive (e.g. Figure 
10 and Supplementary photo 3 and 4). 
Figure 9; HCC that lost expression of CAR but is positive for alternative receptors like CD46 or DSG2 
  
  
                                                     
*8 In one of the sections the uneven staining probably had to do with uneven deparaffinization as the same 
pattern was observed for all the receptors including the αv integrin. 
CAR αvβ6 
CD46 DSG2 
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Figure 10; Expression of the receptors is not tumour-specific 
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Transduction efficacy of the fibre-modified viruses 
Harvesting cells at least 48 hours post infection was found as the most appropriate time point for 
harvesting the cells infected with the replication defective viruses*9 (Supplementary figure 5). The 
transduction efficacy of the fibre-modified viruses in the different cell lines is summarised in Figure 
11. Results from CC-LP-I and CC-SW-I are also included but work on these cell lines was continued 
in more detail by Yi Hsuan Chen [22].  
No significant difference among the viruses was found in Huh7.5. In HepG2 the transduction efficacy 
of vAd5/3(EGFP) was on average 60% better than the rest of the viruses. In CC-SW-I the 
transduction efficacy of vAd5/3(EGFP) [and to a lesser degree of vAd5/FMD(EGFP)], was evidently 
better compared to the rest of the viruses. However, despite the significantly increased efficacy of 
vAd5/3(EGFP) in HepG2 and CC-SW-I, the percentage of infected cells remained much lower 
compared to that of Huh7.5 or CC-LP-I at the same MOI (Figure 12).  
Primary hepatocytes were transduced with all the virus, although unexpectedly vAd5/RGD(EGFP) 
and vAd5/FMD(EGFP) were significantly less effective compared to the other viruses (Figure 13). 
Primary ICCA cells were found to be very resistant to adenovirus transduction and very high MOIs 
were required for successful transduction as measured by flow cytometry. Overall, vAd5/35(EGFP) 
had a markedly higher transduction efficacy, although very high MOIs were required. The very wide 
distribution of the autofluorescence of the uninfected control combined with the low EGFP 
expression by the replication-defective viruses at low MOIs or the shift of the negative population at 
the very high MOIs complicated accurate quantification of the relative transduction efficacies 
(Supplementary figure 7).  
                                                     
*9 For some of the experiments that were done before the time course experiments cells were harvested at 
earlier time points (e.g. 38-45 hours post infection). This didn’t seem to have any significant effect on the 
relative transduction efficacy of the viruses. 
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Figure 11; Comparison of the fibre-modified viruses in the different cell lines 
 
 
The HepG2 and Huh7.5 bar charts represent the averaged results (± SD error bars) from at least 4 independent 
experiments as described in the “MATERIALS AND METHODS” section. The CC-SW-I graph illustrates a 
titration of the viruses. CC-LP-I and CC-SW-I cell lines are discussed in more detail in Yi Hsuan Chen’s thesis 
[22]. **Two-tailed p value < 0.01 compared to any virus - calculated with Excel’s “two sample t-test assuming 
unequal variance”. Statistical significance was even higher (p<0.001) with one-way repeated measures 
ANOVA (pairing the means from independent experiments) followed by the Holm-Sidak method for multiple 
pairwise comparisons (SigmaPlot). 
100%
103,54%
91,92% 81,50% 94,63%
0%
20%
40%
60%
80%
100%
120%
re
la
ti
v
e 
tr
an
sd
u
ct
io
n
 e
ff
ic
ac
y
Huh7.5
100%
163,55%
96,83%
93,67%
111,61%
0%
20%
40%
60%
80%
100%
120%
140%
160%
180%
200%
re
la
ti
v
e 
tr
an
sd
u
ct
io
n
 e
ff
ic
ac
y
HepG2
0,00%
20,00%
40,00%
60,00%
80,00%
100,00%
0,1 1 10 100 1000
%
 o
f 
p
o
si
ti
ve
 c
e
lls
virus particles/cell
CC-SW-I
vAd5wt(EGFP) vAd5/3(EGFP)
vAd5/RGD(EGFP) vAd5/FMD(EGFP)
vAd5/35(EGFP)
100% 85,41% 89,80%
88,10%
72,36%
0%
20%
40%
60%
80%
100%
120%
re
la
ti
ve
 t
ra
n
sd
u
ct
io
n
 e
ff
ic
ac
y
CC-LP-I
** 
  
 37 
Figure 12; Transduction efficacy of vAd5/3(EGFP) in the different cell lines 
 
 
Figure 13; Transduction of primary hepatocytes 
  
Primary hepatocytes were isolated form a marginal liver donor (see also Supplementary figure 10). 
5*10^5 cells were seeded in 24 well plates, although the final cell number was probably much less. 
Results represent the mean (± SD error bars) from quadruplicate wells. Using SigmaPlot’s Holm-
Sidak method for multiple pairwise comparisons following one way ANOVA, the lower transduction 
by vAd5/FMD and vAd5/RGD was statistically significant comparing to the other three viruses. At 
the highest dose, pairwise comparisons resulted in p values of at least <0.031 (*) for vAd5/FMD, and 
at least <0.002 (**) for vAd5/RGD. At the lowest dose, the p values were at least < 0.003 (**), apart 
from the pairwise comparisons with vAd5 which weren’t significant at this dose. 
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Co-infection experiments 
As shown by the time course experiments (Supplementary figure 5), it takes at least 48 hours post-
infection for the replication defective viruses to express high enough levels of EGFP. However at the 
same time the cells keep replicating*10 which may result in dilution of EGFP and reduction of the 
calculated percentage of positive cells [especially if uninfected cells have a higher chance to replicate 
due to adenovirus-induced cell cycle arrest of infected cells (e.g. [75])]. The co-infection of cells with 
the EGFP-expressing replication defective fibre-modified adenoviruses and the replication 
competent, reporter-less vAd5wt(WTp-E1AΔ24)(no-EGFP) results in higher expression of EGFP 
and allows harvesting cells at a much earlier time point. However, the transduction of HepG2 cells 
remained much lower compared to the transduction of Huh7.5 (Supplementary figure 6), therefore 
excluding the above-mentioned problems as a cause for the low transduction observed. Similarly, 
lower transduction of HepG2 cells was observed with the replication-selective viruses. The relative 
transduction efficacy of the viruses in the co-infection experiments was similar to that shown in 
Figure 11. 
Flow cytometry staining for the viral receptors and CD40 
The levels of expression of the viral receptors are shown in Figure 14. Unexpectedly, CD46 was not 
detected with flow cytometry. Furthermore, there doesn’t seem to be a good correlation between the 
levels of the viral receptors and the transduction efficacy. For example, CAR seems to be expressed 
by all the cell lines tested (Figure 15). A more detailed discussion is given in the “DISCUSSION” 
section. Regarding CD40 expression, CC-LP-I showed the highest level of expression followed by 
CC-SW-I. No or very low levels of CD40 were detected in the rest of the cell lines (Figure 16). 
These results were confirmed with a second independent experiment. No significant difference was 
detected using non-enzymatic harvesting (with 10mM EDTA in PBS), therefore excluding sensitivity 
                                                     
*10 Despite the use of 2% FCS medium, the cell count at the day of harvesting was found to be twice or more 
compared to the cell count at the day of the infection. Note that uninfected wells were used for the cell counts. 
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to trypsinization as a confounding factor (data not shown). It is worth noting that none of the 
polyclonal antibodies used for IHC (e.g. anti-αvβ6, anti-DSG2, anti-CD46, anti-β5, anti-β8) detected 
the target antigens with flow cytometry even when the corresponding monoclonal antibodies were 
used successfully (e.g. 6D8 versus the polyclonal anti-DSG2, or 53a.2 versus the polyclonal anti-
αvβ6, Supplementary figure 12). This could suggest unsuitability of these antibodies for flow 
cytometry applications or a problem with the secondary anti-rabbit antibody used (e.g. lack of 
recognition by the secondary antibody or too low concentration). 
Figure 14; Expression of the viral receptors as detected by flow cytometry 
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Figure 15; CAR expression by the different cell lines as detected by flow cytometry 
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Figure 16; CD40 levels as detected by flow cytometry 
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Blocking experiments 
To further confirm the receptor specificity of the fibre-modified viruses blocking experiments were 
performed. For the blocking experiments the CC-LP-I and CC-SW-I cell lines were selected. CC-LP-
I was selected because of the reproducibly low overlap between the negative and positive population 
in flowcytometry. CC-SW-I was selected because of the significant differences of transduction 
efficacy observed, as presented previously. Regarding the CC-SW-I cell line, only vAd5/3(EGFP) 
and vAd5/FMD(EGFP) were tested, since the rest of the viruses showed very low transduction. 
Ideally, similar blocking experiment should have been done with the HCC cell lines. The results are 
summarised in Figure 17 and Figure 18 (see also Supplementary figure 13 for some of the 
corresponding flow cytometry histograms). For the protocol used see page 26. 
Transduction of CC-SW-I by vAd5/FMD was significantly blocked by 53a.2 (the monoclonal 
antibody against αvβ6) and to a lesser degree by the anti-αv monoclonal antibody (L230). RMCB 
(the monoclonal antibody against CAR) had a very small effect on the infection of CC-SW-I by 
vAd5/FMD, confirming that the primary receptor used for infection of CC-SW-I is αvβ6. 
Interestingly, the reverse results were found using the CC-LP-I cell line, i.e. significant blocking of 
infection by RMCB pre-incubation and very small effect of 53a.2 suggesting that the primary 
receptor for infection of CC-LP-I cells is CAR. RMCB also had a significant inhibitory effect on 
infection by vAd5/RGD(EGFP) while unexpectedly the effect on vAd5wt(EGFP) infection was very 
small. This is discussed further later (“DISCUSSION” section). The anti-CD46 monoclonal antibody 
(MEM-258) blocked significantly transduction of CC-LP-I by vAd5/35(EGFP) while the same 
antibody had very little effect on transduction by vAd5wt(EGFP) therefore confirming that 
vAd5/35(EGFP) uses CD46 as its primary receptor. Significant blocking of vAd5/3(EGFP) was not 
achieved, even with very high antibody concentration (up to 40μg/ml of 6D8, the monoclonal 
antibody against DSG2), but this was not unexpected as 6D8 had shown only a small inhibitory effect 
previously [26]. None of the polyclonal antibodies tried (anti-CAR, anti-CD46, antiDSG2, anti-αvβ6- 
see Table 3) had any significant blocking effect. 
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Figure 17; Blocking of fibre-modified viruses- CC-LP-I cell line 
 
  
  
The data represent the mean of duplicate wells (± SD error bars). The asterisks (*) next to the 
antibodies indicate data averaged from two independent experiments (duplicate wells per 
experiment). See Table 3 for the antibodies used. Two-tailed p values compared to the control; 
***<0.001,**<0.01,*<0.05. Calculated with Excel’s “two sample t-test assuming unequal variances”.  
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Figure 18; Blocking of fibre-modified viruses- CC-SW-I cell line 
Where results from duplicate wells were available the mean (±SD error bars) are shown. *two-tailed 
p value < 0.05. Calculated with Excel’s “two sample t-test assuming uneven variances”. 
Further experiments on transduction 
Previous experiments showed very ineffective transduction of CC-SW-I and primary ICCA cells 
despite expression of CAR as detected by flow cytometry. A possible explanation might be that the 
receptors might not be available for binding (e.g. hidden in tight junctions [76, 77]). This possibility 
was supported by the fact that infection of CC-SW-I cells in suspension significantly improved the 
transduction efficacy (Figure 19). However the same effect was not seen in primary ICCA cells, 
where infection with up to 5000 vp/cell resulted in a very low percentage of positive cells (Figure 
19). 
An MTT assay of primary ICCA cells was set up before the low transduction efficacy was yet 
known. Even at doses of more than 2000 vp/cell only very few fluorescent cells were detected. 
Therefore instead of doing the MTT assay the cells were followed to see if the virus can spread from 
the very few infected cells. Indeed, the virus could successfully spread from infected cells to 
neighbouring cells (Figure 20).  
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Figure 19; Infection of CC-SW-I and primary ICCA in suspension 
 
1.3*10^6 CC-SW-I cells were seeded in a 6-well plate and infected; (A) immediately with 1.3*10^8 
vp of vAd5wt(WTp-E1AΔ24) or (B) the next day with 2*10^8 vp of vAd5wt(WTp-E1AΔ24). Cells 
were harvested and analysed with flow cytometry the next day after infection.  
 
  
(C) 4*10^5 primary ICCA cells were seeded in a 24 well plate and infected immediately with the 
replication-selective viruses. The results shown here represent infection with 5000 vp/cell of 
vAd5wt(WTp-E1AΔ24). 
 
Figure 20; Cell-to-cell spread in primary ICCA cells 
  
4*10^4 primary ICCA cells were seeded in a 96-well plate and infected the next day. The highest 
dose was 1.3*10^8 vp. The arrow in the first photo indicates one of the very rare fluorescent cells, 
from a well infected with the highest dose of vAd5wt(WTp-E1AΔ24). Interestingly, despite the very 
low initial transduction efficacy, the virus could spread efficiently to neighbouring cells.  
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Comparison of the replication-“selective” viruses 
Analysis of the replication-selective viruses with flow cytometry was complicated by a significant 
and variable shift of the uninfected population suggesting uptake of EGFP by uninfected cells. This 
was supported by the fact that mixing cells from uninfected and infected wells during the harvesting 
process resulted in the same shift (see page 73). So more focus was placed on the MTT assays which 
are also more informative regarding the cytotoxicity of the viruses. Briefly, the flow cytometry 
experiments with the replicating viruses showed a similar transduction efficacy pattern to that of 
vAd5wt(EGFP), i.e. higher transduction of Huh7.5 compared to HepG2 cells. Furthermore, the 
intensity of the fluorescence of all the viruses was much higher compared to that of the replication-
deficient viruses and there was a clear separation of the negative and positive population within 24 
hours post-infection. This suggests that all the viruses were replicating efficiently. There were small 
differences in the transduction efficacy and the mean fluorescence intensity between the viruses but 
they did not correlate with their cytotoxicity in MTT assays. 
As expected from the previous results on the transduction efficacy, the MTT assays showed that the 
cytotoxicity of the viruses in HepG2 was lower compared to that in Huh7.5 at the same dose (Figure 
21). The differences between the viruses were small. Unexpectedly, the viruses were not found to be 
selective in an MTT assay of primary hepatocytes isolated from a marginal liver donor (Figure 22) 
(see also Supplementary figure 8-9). vAd5wt(hTERTp-E1A) and vAd5wt(E2Fp-E1AΔ24) seem a bit 
more selective than vAd5wt(WTp-E1AΔ24) at the lowest MOIs used.  
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Figure 21; Comparison of the replication-selective viruses in HCC cell lines with MTT assay 
  
  
10000 (Huh7.5) or 20000 (HepG2) cells were seeded in 96-well plates and infected the next day with 
3-fold serial dilutions of the viruses. The MOIs (IU/cell) are calculated based on the estimation that 
cell number increased by about 50% from seeding to infection. Data shown represent the mean ± SD 
from triplicate wells. 
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Figure 22; MTT assay in primary hepatocytes (day 3) 
* 50000 primary hepatocytes isolated from a marginal liver donor were seeded in a 96-well plate. 
However the wells required a lot of washing (see Supplementary figure 10) and the final number of 
hepatocytes was much less. Here the MOI is calculated estimating 20000 cells per well. . Data shown 
represent the mean ± SD from quadruplicate wells. 
 
Effect of CD40L on viability and comparison of wtCD40L vs ncCD40L 
The CD40L-expressing viruses*11 were tested with MTT assays in the HCC cell lines (HepG2 and 
Huh7.5). A similar comparison was done by Yi-Hsuan, Chen in the CC-LP-I cell line [22]. 
vAd5wt(wtCD40L) and vAd5wt(ncCD40L) didn’t offer any advantage in Huh7.5 and HepG2 
compared to vAd5wt(EGFP) (Figure 23A and B). In HepG2 there was little cytotoxicity even at the 
highest dose (about 330 IU/cell), while in Huh7.5 the cytotoxicity of the CD40L-armed viruses was 
not greater than that of vAd5wt(EGFP). Furthermore, combining the replication-competent 
vAd5wt(E2Fp-E1AΔ24) with the replication-defective CD40L-expressing viruses didn’t offer any 
advantage compared to combination with the replication-defective vAd5wt(EGFP)*12 (Figure 23C 
and D). Therefore, there doesn’t seem to be any synergism between oncolysis and CD40L expression 
                                                     
*11 Expression of CD40L was confirmed by Dr Searle with flowcytometry staining (of A549 cells infected with 
increasing MOI of the CD40L viruses) with an FITC-labelled anti-human CD154 antibody (Biolegend). A dose 
dependent increase of CD154 was seen, confirming expression of the transgene by the viruses. 
*12 Although vAd5wt(EGFP) may not be an appropriate control as it has an intact E3 region, while the CD40-
ligand viruses are E3 deleted. 
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in these cell lines in vitro. However, in Huh7.5 vAd5wt(ncCD40 L) seems to be slightly better than 
vAd5wt(wtCD40L) (Supplementary figure 11). The difference in HepG2 was much smaller. 
Figure 23; MTT assay of CD40L-expressing viruses.  
   
  
(A) and (B); infection with each virus alone (doses plotted as vp because the corresponding IU for 
vAd5wt(EGFP) is not known). (C) and (D); combination with vAd5wt(E2Fp-E1AΔ24). MTT assays 
were done at different time points (up to day 7). Different doses of the CD40L-armed viruses in the 
combination experiments were also tried (Huh7.5; 12 IU/cell, 4 IU/cell, 1.4 IU/cell, 0.5 IU/cell. 
HepG2; 36 IU/cell, 12 IU/cell, 4 IU/cell, 1.4 IU/cell). At all time points and doses the combination 
with vAd5wt(EGFP) was at least as good as the combination with the CD40L-armed viruses. One IU 
of vAd5wt(wtCD40L) and vAd5wt(ncCD40L) corresponds to about 16 and 28 vp respectively. 
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Comparison of the fibre-modified adenoviruses 
Four fibre-modified adenoviruses and a wild type fibre virus, all replication defective and EGFP-
expressing, were constructed and compared side-by-side for their transduction efficacy and 
selectivity. Apart from the fibre-modification the rest of their genome, and therefore the rest of the 
sviral capsid, is identical for all the viruses. Therefore any differences observed can be attributed to 
the modified fibres.  
A problem with comparing the fibre -modified viruses with each other is the lack of an appropriate 
control cell line. Differences in the transduction efficacy may reflect differences in the virus prep 
quality (particle-to-infectivity ratio) rather than the effect of the fibre modification. An ideal control 
would be a cell line that is transduced by all the viruses equally effectively. Despite the lack of such a 
control some conclusions can be made. For example, in most cases the differences between the 
viruses in the different cell lines are insignificant or very small, suggesting that there aren’t 
significant differences in the virus prep quality. Therefore, the superior efficacies of vAd5/3(EGFP) 
in HepG2 and especially of vAd5/3(EGFP) and vAd5/FMD(EGFP) in CC-SW-I are valid, although 
an accurate quantification without a proper control is not possible. The results about vAd5/35(EGFP) 
differ from that previously published. A virus with the 5/35 chimeric fibre was reported to have a 
significantly improved transduction efficacy in Huh7 and HepG2 compared to a virus with the wild 
type fibre [23].  
Despite the lack of a control to take into account differences in the virus prep quality, conclusions 
about the relative transduction of each virus in primary hepatocytes compared to cancer cell lines can 
still be made. Quantifying the transduction efficacy in primary hepatocytes was complicated by the 
high amount of debris, the variable number of surviving hepatocytes and the uncertainty of defining 
the hepatocyte population in flow cytometry. However it seems that primary hepatocytes were 
transduced at least as effectively if not better compared to HepG2 or CC-SW-I cells but probably less 
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effectively compared to Huh7.5 or CC-LP-I. Transduction of hepatocytes by vAd5/FMD(EGFP) and 
vAd5/RGD(EGFP) was significantly less compared to the rest of the viruses. 
The tendency of vAd5/FMD(EGFP) and vAd5/RGD(EGFP) to show slightly lower transduction 
efficacy in most cell lines may represent a difference in the virus prep quality. Alternatively, a 
weaker binding to CAR receptor may explain these results and the results of the blocking 
experiments (transduction by these viruses was blocked with an anti-CAR antibody significantly 
more than the virus with the wild type fibre). Another possible explanation for the results of the 
blocking experiments is that the insertion of the FMD and RGD motifs in the fibre knob might allow 
more effective antibody-mediated steric hindrance of binding to CAR. Interestingly, reduced liver 
uptake in vivo of the Ad5/FMD fibre-modified has been reported in the original paper describing this 
modification, although this was attributed to altered electrostatic interactions with blood components 
and Kupffer cells, and therefore cannot explain the in vitro result reported here [29]. On the other 
hand, increased uptake by most organs has been reported for a virus with the RGD-modified fibre 
[78]. 
As already mentioned, a short absorption time (40 minutes) was selected for comparing the 
transduction efficacy assuming that this design would be more sensitive at detecting differences in 
the transduction efficacy. However, it would have been interesting to do similar experiments using 
longer absorption times as the binding affinity to the cells or internalization kinetics of the viruses 
might have played a significant role when using the shorter absorption time. For example, a virus 
with low binding affinity and slower internalization kinetics may be less likely to transduce a cell 
within 40 minutes and more likely to be washed away during the washing step. This might explain 
the unexpected lack of advantage of vAd5/RGD(EGFP) and vAd5/FMD(EGFP) (with the exception 
of the CC-SW-I cell line) over vAd5wt(EGFP), despite their extended receptor repertoire. As 
suggested by the results of the blocking experiments it is likely that these viruses bind to CAR with 
lower affinity. It is possible that longer absorption times would have allowed more effective 
utilization of the extended receptor repertoire. Nevertheless, in the original paper describing the 
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5/RGD modified fibre, an absorption time of just 30 minutes was used and the virus was significantly 
better than the corresponding wild type fibre virus [28]. 
Correlation with the flow cytometry staining for the receptors 
Interestingly, the expression of the receptors as detected by flow cytometry showed little correlation 
with the transduction efficacy of the viruses. For example, CAR was highly expressed by all cell lines 
but transduction varied significantly, from the very ineffective transduction in the primary ICCA cells 
and CC-SW-I to the high transduction efficacy in Huh7.5 and CC-LP-I. Lack of correlation between 
expression of CAR and the transduction efficacy has been reported previously [79-81]. One possible 
explanation is that the receptors might not be available for binding (e.g. hidden in tight junctions [76, 
77]). This might be the case with the CC-SW-I cell line for example*13, as infection in suspension 
significantly improved the transduction efficacy, and resulted in very high levels of fluorescence 
intensity, at least comparable if not better to the more easily transducible cell lines. However the 
same does not apply to the primary ICCA cells which were very ineffectively transduced even at high 
MOIs and in suspension. 
Many other factors apart from the presence and levels of the receptor can affect the transduction 
efficacy as defined by the percentage of cells expressing the transgene (in this case EGFP). 
Adenoviral transduction involves many steps; binding to the cell, internalization of the virus, 
endosomal escape, trafficking to the nucleus and finally expression of the transgene. Furthermore, 
anti-viral responses may also play a role. An obstacle in any of these steps could explain the 
ineffective transduction of the primary ICCA cells. For example, blocking of adenovirus trafficking 
to the nucleus has been reported previously as the reason for inefficient transduction in human 
pancreatic cancer cell lines [82]. Interestingly, despite the low efficiency of the cell-free virus to 
infect the primary ICCA cells, efficient cell to cell spread was demonstrated here. 
                                                     
*13 Although it is questionable whether CC-SW-I cells can form an epithelial monolayer with tight junctions in 
the culture system used. 
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The flow cytometry staining results reported here have some limitation: 
 Negative control cell lines should have ideally been included, e.g. for CAR since all the cell 
lines tested showed high positivity. However the results for Huh7.5 and HepG2 are similar to 
that published previously, i.e. both HCC cell lines are positive for CAR and CAR expression 
in Huh7 is higher than in HepG2 [23].  
 Lack of an appropriate rat isotype control casts doubt on the results regarding αvβ6 receptor 
expression. Furthermore, b6 integrin has been previously reported to be very low in HepG2 
using RT-PCR and immunocytochemistry [32]. However similar discrepancies have been 
reported in the literature before, as discussed later for the CD40 expression by HepG2 cells. 
The passage history of the cell line may play a role in such discrepancies, as the HepG2 cell 
line was established more than 30 years ago. 
 Unexpectedly CD46 was not detected with either MEM-258*14 or the polyclonal anti-CD46 
used for immunohistochemistry (although none of the antibodies used for IHC detected the 
antigens with flow cytometry). The fact that MEM-258 can very effectively and specifically 
block transduction by Ad5/35 indicates that the receptor was present. Furthermore, Huh7 and 
HepG2 were found positive for CD46 with flow cytometry in a previous study [23]. Non 
enzymatic harvesting (with 10mM EDTA in PBS) didn’t make a difference therefore 
excluding loss of the receptor due to trypsinization. A possible explanation is lack of 
recognition of MEM-258 by the secondary antibody, although the antibody worked for the 
rest primary antibodies of the same isotype. Alternatively, antigen internalization or capping 
and shedding may have caused loss of the antigen. However, doing the staining on ice should 
have limited these issues. Since viability of the cells was not an issue maybe sodium azide 
should have been added to the FACS buffer, to further minimize surface antigen loss. 
 None of the polyclonal antibodies that were used for immunohistochemistry detected the 
target antigen in flow cytometry, even when the antigen was detected by the corresponding 
                                                     
*14 The monoclonal antibody against CD46 
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monoclonal antibodies. Therefore, the lack of detection of integrins b3 and b5 may not be 
real. However, knowing the levels of these integrins could have explained the lack of 
correlation of transduction with the levels of CAR, as they are important for virus 
internalization (e.g. [80, 83]). 
Blocking experiments to confirm the receptor specificity of the viruses 
The results from the blocking experiments confirmed that vAd5/35(EGFP) uses CD46 as a receptor. 
The use of DSG2 by vAd5/3(EGFP) could not be confirmed, however this was expected as the 
antibody used here (6D8) had little effect on the binding of the virus in a previous study [26]. The use 
of integrin αvβ6 by vAd5/FMD(EGFP) was confirmed in CC-SW-I, while RMCB (the anti-CAR 
antibody) had a non-significant effect in this cell line. This is in agreement with what would be 
expected from the transduction experiments, as vAd5/FMD(EGFP) was significantly more effective 
than vAd5wt(EGFP) in CC-SW-I. Unexpectedly, in CC-LP-I vAd5/FMD(EGFP) infection was 
significantly blocked by RMCB but not by 53a.2 (the anti-αvβ6 antibody) despite that αvβ6 was 
detected with flow cytometry. Furthermore, vAd5/RGD(EGFP) infection was also significantly 
inhibited by RMCB while the effect on vAd5wt(EGFP) was much less. As discussed previously, this 
might have to do with lower binding affinity to CAR or more effective antibody-mediated steric 
hindrance in the case of the RGD and FMD modified viruses, although it is unclear why the viruses 
could not use the alternative receptors. 
Immunohistochemistry of HCC for the viral receptors 
Immunohistochemistry was performed to compare the level of expression of the viral receptors 
between HCC and non-tumour tissues. Expression of CAR has been reported previously to be 
variable in tumours, including HCC [23, 24]. Here, most tumours were found to maintain expression 
of CAR (6 of 7), although in 2 cases CAR was focally expressed and in another 2 the staining 
intensity was lower compared to the corresponding “normal” tissue. In cases where CAR expression 
was lost or reduced, other receptors like DSG2 or CD46 were highly expressed. However, none of the 
receptors was found to be specifically expressed in HCC compared to non-tumour liver. It has been 
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reported previously for CD46 that much higher levels are detected in HCC compared to diseased non-
tumour or normal liver [23, 31]. However, this was not replicated here. According to five HCC 
sections that included both the tumour and the surrounding margin, CD46 was expressed by both 
tissues, and the intensity of the staining wasn’t significantly different. The clinical relevance of IHC 
however is questionable considering the possible lack of correlation between receptor expression and 
transduction efficacy as shown for the cell lines. 
Replication selective adenoviruses 
Three conditionally replicating adenoviruses made in a parallel project [22], vAd5wt(hTERTp-
E1AΔ24), vAd5wt(WTp-E1AΔ24) and vAd5(E2Fp-E1AΔ24), were compared side by side in HCC 
cell lines and primary hepatocytes. No significant differences were found among the three viruses 
with MTT assays in HepG2 and Huh7.5 cell lines. Furthermore, an MTT assay using freshly isolated 
hepatocytes from a marginal liver donor (steatotic liver), demonstrated lack of selectivity of the 
viruses except possibly at the very lowest dose. Moreover, the detection of good levels of 
fluorescence just 17 hours post-infection of primary hepatocytes (from a liver with cryptogenic 
cirrhosis) suggests viral replication, since expression of transgenes inserted in the E3 region (in this 
case EGFP) is linked with transcription of E1A and viral replication [84]). However, the quality of 
the hepatocytes used for the MTT assay may be questionable (Supplementary figure 10). 
It is also important to note that HCC develops from a background of a chronically diseased liver. This 
might affect the selectivity of the viruses. The liver has a remarkable regenerative capacity and 
chronic liver disease might activate pathways similar to that activated in tumours and exploited to 
achieve tumour-specificity. Therefore, using normal hepatocytes in vitro to demonstrate the 
selectivity of the viruses may not be clinically relevant, especially for HCC patients with background 
liver disease. For example, it has been reported that hTERT promoter is activated during liver 
regeneration [85]. Telomerase activity or hTERT expression has also been demonstrated in humans 
in regenerative and precancerous liver lesions [86-88]. Furthermore, the MOI used for infection is 
important as higher MOIs, e.g. after intratumoural injection of the virus into the liver, may be able to 
  
 56 
override the selectivity of the virus. It has been previously reported that an hTERT-E1A controlled 
adenovirus showed very little toxicity against primary hepatocytes (e.g. [35, 89]). However, only low 
MOIs were used and the condition of the livers from which the hepatocytes were isolated is not 
described. Similarly, using normal fibroblast (e.g. [35, 90]) to demonstrate selectivity might also be 
irrelevant to HCC patients.  
Nevertheless, conditionally replicating adenoviruses have been used previously in clinical trials with 
little reported toxicity [36-43]. However, the lack of significant hepatotoxicity in clinical trials in 
cases of extrahepatic administration may have to do with the fact that the virus might not be reaching 
hepatocytes at a high enough MOI to override selectivity, e.g. due to elimination of the virus by 
tissue macrophages, like Kupffer cells in the case of the liver. Alternatively, the microenvironment of 
a diseased liver may not be favourable for the virus (reviewed in reference [91]). Results about safety 
from patients without liver disease may not be relevant to HCC patients, for the reasons explained 
above, but also because patients with HCC might be less tolerant to hepatotoxicity due to pre-existing 
liver dysfunction.  Furthermore, intrahepatic intralesional administration of the viruses may pose a 
greater risk compared to extrahepatic administration, as a high MOI would be injected directly into 
the liver parenchyma. Intralesional administration of ONYX-015 in hepatobiliary tumours was 
reported as safe however this virus is significantly attenuated compared to the viruses tested here and 
patients were carefully selected (good performance status, adequate organ function, HBV 
excluded)[92]. Moreover, the interpretation about the safety might be questionable (3 patients died 
“of causes felt to be unrelated to study treatment”; serious toxicities were described as uncommon but 
affected 6 out of 19 patients, and cases of hepatic toxicity including one liver failure were attributed 
to disease progression). In an earlier study, ONYX-015 was also well-tolerated when administered 
intrahepatically, but no antitumour effect was seen in 4 of the 5 patients [93]. Whether the newer 
more potent and armed adenoviruses will be safe in HCC patients remains to be seen. An oncolytic 
immunotherapeutic vaccinia virus has already completed early clinical trials with promising results 
[94].  
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CD40L-armed adenoviruses and oncolytic immunotherapy 
The CD40L-expressing viruses were not found to increase the cytotoxicity in HepG2 and Huh7.5, 
either alone or when co-infected with the replication-competent virus, compared to vAd5wt(EGFP). 
However, the comparison with vAd5wt(EGFP) is complicated by the fact that the CD40L-viruses are 
E3-deleted while the E3 region of Ad5wt(EGFP) is intact. This might explain the higher cytotoxicity 
of the co-infection with vAd5wt(EGFP) versus the co-infection with the CD40L expressing viruses, 
especially if the EGFP transgene in Ad5wt(E2Fp-E1AΔ24) affects the expression of other E3 region 
products (e.g. the adenovirus death protein [16]). Ideally an E1/E3 deleted virus not expressing the 
CD40L should have been used as a control. Alternatively, the CD40L transgene would be inserted 
into the E3 region of one of the replication-selective viruses, and the corresponding virus without this 
insertion would be used for comparison. 
According to the flow cytometry staining, CD40 expression in the HCC cell lines was very low or 
undetectable, which might explain the previous results. The literature regarding the expression of 
CD40 by HepG2 cells is conflicting. Cruickshank et al [95] found expression of CD40 in biliary 
epithelial cell-derived cell lines and CC-SW-I but not in HCC-derived cell lines (including HepG2). 
Sugimoto et al [50] on the other hand have shown expression of CD40 by HepG2 cells with RT-PCR 
and flow cytometry staining. However CD40 activation did not induce apoptosis in HepG2 cells [50]. 
Depending on the cells and conditions, CD40 activation can both promote cell viability or induce cell 
death [50, 63, 96-99]. Regarding CC-LP-I and CC-SW-I, the results reported here are similar to that 
reported by Humphreys et al [63], i.e. both are positive and CD40 expression is higher in CC-LP-I 
than in CC-SW-I. 
However the expression of CD40 by cell lines might not be representative of the in vivo situation as 
CD40 expression can be upregulated by inflammatory cytokines [50]. Also it has been reported 
previously that 60% of HCCs are positive for CD40 expression by immunohistochemistry [50]. 
While CD40 was not detected in normal or cirrhotic liver or in chronic hepatitis in that study [50], 
later the same authors found CD40-positive hepatocytes in HCV-associated chronic liver disease 
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[96]. Here CD40 was found positive in 3 of the 4 tumours stained for CD40, but was also detected in 
non-cancerous liver. The sections including non-tumour margin and stained for CD40 so far were 
from livers with chronic viral hepatitis. Unexpectedly CD154, the CD40 ligand, was also found 
strongly positive in most sections. Ideally, an appropriate negative control tissue or cell line should 
be used to exclude non-specific binding of the antibody. Nevertheless, the relevant isotype control 
antibody didn’t show non-specific staining. Furthermore, according to the abstract of a Korean paper 
[100] CD154 was detected in 37.5% of 96 resected HCCs, and there were cases expressing both 
CD40 and CD40L. 
The inefficacy of the CD40L viruses in vitro doesn’t mean that the viruses will be ineffective in vivo, 
as has been demonstrated before [49]. Apart from any direct effect on tumour cells, CD40L 
expression might still be useful because of its immunostimulatory activity (reviewed by Ma and 
Clark [46]). Adenovirus mediated CD40L gene therapy (reviewed by Ullenhag and Loskog [101]) 
has been used successfully to treat HCC in vivo in animal models [102, 103] and this effect was 
shown to be immune-mediated rather than a direct effect on the tumour cells by CD40L. 
Furthermore, CD40L-armed adenoviruses have been used safely in early clinical trials and showed 
evidence of anti-tumour activity [104, 105]. However, it has been reported that activation of CD40 in 
HepG2 might facilitate immune escape by up-regulating negative co-stimulatory molecules [106] and 
recent studies suggested that the CD40/CD40L signalling can potentially have an immunosuppressive 
effect [107], although this was shown for the soluble CD40L and not the membrane bound form as it 
would be delivered by an oncolytic vector. For example, the membrane bound CD40L can more 
potently induce apoptosis, while the soluble form might promote tumour survival [52, 108]. 
Therefore, it is important to understand under what conditions CD40 activation can have unwanted 
effects. 
Further discussion  
 Are the results reported here clinically relevant? The results from the most clinically 
relevant experiment, the MTT assay on freshly isolated primary hepatocyte, were 
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unexpected. Further experiments in primary hepatocytes or primary biliary epithelial cells are 
needed to confirm or reject these results. However, whether freshly isolated hepatocytes are a 
good model for predicting the in vivo selectivity of the viruses is also questionable, as 
discussed previously. Another issue is that the cell lines used were established more than 20-
30 years ago and have a long passage history, therefore their relevance to their tissue of 
origin is questionable. Furthermore, HepG2 and Huh7 are both established from well 
differentiated HCC, while Huh7.5 is just a subclone of the original Huh7 cell line selected for 
being permissive to hepatitis C virus replication. Moreover, using immunohistochemistry as a 
predictive factor for the transduction efficacy of a virus against a tumour does not seem 
appropriate considering the possible lack of correlation between the receptor expression and 
the transduction of the cell lines. To complicate things more, interaction of the virus with 
blood factors (clotting factors, complement, natural antibodies, blood cells) (e.g. [6-9]), in the 
case of intravascular administration of the virus, significantly reduces the relevance of the in 
vitro results. For example, transduction of hepatocytes in vivo, is considered to be 
independent of CAR or integrin binding, and more likely has to do with coating of the viruses 
by blood factors like the clotting factor X [8, 9]. The in vitro experiments on transduction 
could be made more clinically relevant e.g. by preincubation of the viruses in 
blood/plasma/serum before doing the infection. Selecting an appropriate anticoagulant will 
be important as the commonly used anticoagulants for blood collection (EDTA, citrate, 
heparin) can significantly affect viral transduction and the interaction with the blood factors 
[8, 109]. 
In the end, the only way to safely predict the effect of a virus in a specific tumour is to test 
the virus in that specific tumour. For example, ex vivo testing of oncolytic viruses in tumour 
biopsies is possible (e.g. [110]).  Alternatively, a “window of opportunity” trial design (i.e. 
administering the treatment under investigation during the window period from diagnosis to 
planned surgery and testing the effect of the treatment on the resected tissue) could offer 
important and clinically relevant information, e.g. about the biodistribution of the fibre-
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modified viruses or the selectivity, anti-tumour effect and immunomodulatory effects of the 
replication-selective and CD40L-expressing viruses. A “window of opportunity” trial of an 
oncolytic adenovirus in colon cancer has recently been presented in the 2014 ASCO Annual 
Meeting [111].  
 Oncolytic immunotherapy: More and more emphasis is placed on the immunostimulatory 
effects of oncolytic virotherapy, and this has been the focus of many recent review papers 
(e.g. [19, 45, 112-114]). The virus mediated immunogenic cell death combined with 
expression of immunostimulatory molecules has the potential to overcome the 
immunosuppressive/ tolerogenic tumour microenvironment and induce a durable immune-
mediated anti-tumour effect. Adenoviruses can be armed with many other 
immunostimulatory molecules apart from CD40L (e.g.[45, 112]). It would also be interesting 
to confirm whether (and which) immunostimulatory molecules can reverse the 
immunosuppressive phenotype of immune cells of the tumour microenvironment to an 
immunostimulatory phenotype. It has been demonstrated for example that CD40 activation 
can convert tolerogenic dendritic cells to immunostimulatory (e.g. [115-117]), although again 
the reverse effect, i.e. the induction of a tolerogenic dendritic cell phenotype by CD40L, has 
also been reported [118]. Combining oncolytic viruses with such immunostimulatory 
molecules can further enhance immunogenicity by induction of immunogenic cell death [49], 
and allows tumour targeted delivery and intratumoural amplification of the treatment 
therefore potentially minimizing systemic toxicity. 
 Sequential combination with other oncolytic viruses; Repeated dosing of oncolytic 
adenoviruses is hindered by neutralising antibodies and anti-viral immunologic memory. One 
way of overcoming this problem is with sequential administration of antigenically different 
oncolytic viruses, a strategy that can also potentially have a prime and boost anti-tumour 
immune effect [119, 120]. An oncolytic immunotherapeutic vaccinia virus has already 
successfully completed early clinical trials in HCC [94]. If oncolytic adenoviruses are also 
proven safe for HCC then a sequential combination of the two viruses seems promising. 
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Supplementary methods 
Plasmid mini-preparation and restriction digestion 
Colonies from selective plates were grown overnight in 10 ml Veg LB at 32oC. 700μl of the 
overnight cultures were transferred in Sarstedt micro-tubes with 300μl of 50% glycerol in H20 and 
stored at -80oC. Plasmids were mini-prepped with an alkaline lysis method; Overnight cultures were 
centrifuged for 5 minutes at 3750rpm, 4oC (Beckman GS 6R, GH-3.8 rotor). The supernatant was 
poured off, pellets were resuspended in the volume left and the tubes were transferred to ice buckets. 
Then 300μl of solution I (50mM glucose, 25mM Tris pH 8, 10mM EDTA) were added followed by 
150μl of lysozyme solution (Sigma-Aldrich, L6876) (10mg/ml freshly dissolved in solution I) and 
tubes were left on ice for 10 minutes to digest the bacterial cell walls. Proteins and chromosomal 
DNA were denatured with 900μl of solution II (0.2M NaOH, 1% SDS) for 5-10 minutes on ice. 
Proteins and single stranded chromosomal DNA were then precipitated with 675μl of solution III 
(Potassium acetate; 3M K, 5M acetate; 147g KAc and 57.5 ml glacial acetic acid per 500 ml), 
incubating on ice for 5-10 minutes. Samples were centrifuged for 10 minutes at 3750 rpm, 4oC 
(Beckman GS 6R), supernatant was transferred to clean tubes and nucleic acids were precipitated 
with 1 volume of isopropanol (samples were incubated at -20oC for 20-30 minutes and then 
centrifuged for 10 minutes at 9000rpm- Sorvall, SM24). Pellets were re-dissolved in 300μl T100E5N100 
(Tris 100mM, EDTA 1mM, NaCl 100mM, pH 8) with 10 μg/ml heat-treated RNase A and tubes were 
incubated at 37oC for 1 hour. Samples were then transferred to microcentrifuge tubes for phenol-
chloroform extraction;  
- 1 volume of phenol-chloroform (1:1) was added, samples vortexed and centrifuged at 13000 
rpm, for 1 minute- Heraeus Biofuge Pico. The lower phase was discarded.  
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- 1 volume of chloroform was added and samples were vortexed and centrifuged at 13000rpm, 
for 1 minute. The aqueous phase was transferred to new tubes.  
DNA was precipitated with 2 volumes of ethanol (incubation at -20oC for 20-30 minutes followed by 
centrifugation at 13000 rpm for 10 minutes- Heraeus Biofuge Pico) and pellets were resuspended in 
30μl T10E1 (Tris 10mM, EDTA 1mM, pH 8). Samples were then digested with appropriate enzyme 
followed by agarose gel electrophoresis (0.75 % Agarose MP- Roche, TAE buffer) to confirm the 
expected band pattern. 
 
Plasmid bulk preparation 
Confirmed stocks were cultured in 500 ml Veg LB for 30-48 hours. Cultures were centrifuged for 5 
minutes at 5,000 rpm, 4oC (Sorvall, SLA-1500) and plasmids were maxi-prepped. The method was 
similar to the mini-preps up to the isopropanol precipitations, but with 4ml of Solution I, 1ml of 
lysozyme solution, 10ml of Solution II and 7.5 ml of Solution III. Nucleic acids were precipitated 
with isopropanol (20 minutes at 8000rpm, SLA-1500) and pellets were redissolved in 2.5 ml of 
T50E10 (Tris 10mM, EDTA 10mM, pH 8). Plasmid DNA was purified with caesium chloride- 
ethidium bromide density centrifugation; 3.03 g of CsCl (Invitrogen, 15507-023) were added in 15ml 
tubes. Tubes were tared and the samples were transferred to the tubes. Liquid weight was raised to 
2.75g with T50E10. 275μl EtBr (10mg/ml) were then added and tubes were placed on ice for 10 
minutes. Tubes were then centrifuged for 10 minutes at 9000 rpm (Sorvall, SM24) to precipitate 
RNA. Supernatant was transferred to Beckman Quickseal tubes (into which 20μl of 2% Triton X-100 
were previously added). Extra isopycnic CsCl was added to fill tubes marginally below the neck and 
balance tubes (within 0.1g, ideally less). Tubes were centrifuged in Beckman TLN100 rotor as 
follows; Step 1 at 100,000 rpm for 4h, Step 2 at 55,000 rpm for 30-60 minutes, Step 3 at 0 rpm brake 
setting 9, all at 25oC. The lower plasmid band was drawn with a No 21 needle connected to a 2ml 
syringe and samples were diluted 3 times with T10E1N100. Then a phenol-chloroform extraction was 
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done once (as described above but without the second step of chloroform extraction), followed by 
ethanol precipitation twice. Pellets were redissolved in 100μl of T10E1. DNA concentration was 
measured (SYBR gold-based DNA assay, see later, page 71) and confirmed with restriction 
digestion. 
Transfection and infection for propagation of viruses 
Hek 293 cells were seeded in T25 flasks at about 30% of confluence 2 days before the transfection. 5-
15 μg of purified plasmids were ethanol precipitated one day before the transfection and re-dissolved 
in 175 μl of filter-sterile 10mM Tris-Cl (pH 7.5). For the transfection, 25μl of filter-sterile 2M 
calcium chloride were added to the DNA solution and mixed. The DNA/CaCl2 solution was then 
added drop-wise to 200μl of filter-sterile 2xHEBS (50mM HEPES-NaOH pH 7.05, 0.25 M NaCl, 
1.5mM Na/PO4, 0.1mM EDTA) whilst gently mixing on a vortex mixer. The solution was let to 
stand for 20-30 minutes to allow time for the DNA/calcium phosphate co-precipitate to form. 
Medium of flasks was changed (4ml DMEM 10%FCS +gps) and 40μl of 10mM chloroquine were 
added (chloroquine is lysosomotropic, resulting in endosomal swelling/rupture and is considered to 
help endosomal escape of plasmids). The co-precipitate was then added and flasks were returned to 
incubator for 4-5 hours. Then, a glycerol shock was done to improve the transfection efficiency; 
Medium was removed -> 2ml of 15% glycerol in serum-free DMEM-HEPES were added-> at 90 
seconds the glycerol solution was removed -> at 2 minutes DME-HEPES 2% FCS + gps was added. 
One extra flask was used as mock control (same transfection protocol but without any plasmid DNA) 
and one flask was left untransfected. Successful transfection could be confirmed the next day under a 
fluorescence microscope (Axiovert 25, Zeiss), for viral constructs that express EGFP. Cultures were 
then incubated for a few days, until enough CPE (cytopathic effect) developed to allow harvesting of 
cells by shaking the flasks. Harvested cells were pelleted (2000 rpm, 5 mins- Megafuge 2.0R) and 
redissolved in 1ml of the medium. Virus was released from cells with three freeze-thawing steps (-
80oC to 37oC), cell debris was pelleted (4000 rpm, 10mins-Megafuge 2.0R) and supernatant 
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containing free virus was transferred to Sarstedt micro-tubes for storage at -80oC. Mock controls were 
also harvested the same way. 
The transfection pool was then titrated in 6-well plates (five 3-fold serial dilutions starting from 
100μl of the transfection pool). One well was left uninfected as a negative control. Another well was 
“infected” with 100μl of the mock transfection pool (this was necessary to rule out contamination 
because CPE, although to a lesser degree, was also observed in the mock transfection control 
probably due to the toxicity of the transfection protocol). Viruses were harvested from the lowest 
dilution achieving infection of the majority of the cells to minimize carrying of defective viruses (as a 
result of co-infection with both a defective and a normal virus). Viruses were then propagated 
sequencially in one T75 flask and then in 10x T150 flasks for the virus preparation. T75 flasks were 
infected with 5μl of the 6-well infection pool in 2ml of medium (DMEM-HEPES, 2% FCS, gps) and 
T150 flasks were infected with 12 μl of the T75 pool in 4ml of medium. Flasks were incubated for 1-
2 hours before adding the rest of the medium to increase the efficiency of the infection. 
Virus purification and DNA extraction 
Virus was harvested from 10xT150 flasks in a volume of 9-10 ml of medium. After 3x freeze-thaw 
cycles, debris was pelleted -(4000rpm, 10 mins, Megafuge 11, T41 rotor) and virus-containing 
supernatant was transferred to a new tube. 1:100 vol n-butanol was added and the tube was incubated 
on ice for 1 hour. The tube was then centrifuged again (4000rpm, 10 mins, Megafuge 11) and the 
supernatant was layered on the top of a cesium chloride step gradient. From bottom to top: 2ml of 
CsCl 1.45g/ml, 3ml CsCl 1.32 g/ml, 2ml glycerol 40% and about 5ml of the virus sample + extra 
medium if needed (tubes must be filled to about 5mm below the rim)(Table 5). Tubes were balanced 
and centrifuged for at least 2hours, 25k rpm, 4oC (Beckman Coulter, SW40 Ti rotor). The virus band 
(e.g. Figure 8C) was withdrawn with a 2ml syringe and 21G needle and the sample was desalted 
with a GE PD-10 Sephadex G-25 column. For equilibration of the column and sample elution the 
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A195 storage buffer was used [121]. The sample was then divided in 300μl and 50μl aliquots and 
stored at -80oC. 
A 500μl aliquot was used for extraction of the viral DNA. The sample was heat-inactivated at 56oC 
for 30 minutes. 25μl of 10% SDS + 5 μl of 0.5M EDTA + 5 μl of 0.5M NaCl + 5 μl of proteinase K  
were added to the sample and the tube was incubated at 37oC for 1 hour and then at 56oC in a water 
bath for 30 minutes. DNA was then purified with a phenol-chloroform extraction followed by ethanol 
precipitation (as described above for the minipreps). The extracted DNA was then digested with 
appropriate enzymes to confirm the expected band pattern.  
Table 5; recipes for the gradient solutions 
For 100ml CsCl 1.45 g/ml For 100ml CsCl 1.32 g/ml For 100ml Glycerol 40% 
60.42g CsCl +                        
5ml 1M Tris pH 7.9 
42.24g CsCl +                        
5ml 1M Tris pH 7.9  
40g glycerol, 2ml 0.5M tris 
pH 7.9, 0.5ml 0.2M EDTA, 
H2O to 100ml 
Then dissolve with H2O in about 90ml, adjust pH to 7.9-8.0 
and then adjust final volume to 100ml. 
 
DNA assay 
The assay is performed in a 96-well plate with flat-bottomed wells. For the standard curve 0, 10, 20, 
40, 60, 80, 100, 120, 140 and 160 ng of purified calf thymus DNA were added per well in a final 
volume of 100μl of T10E1. For the samples, 2μl of appropriate sample dilutions were added in a final 
volume of 100μl of T10E1. A 200-fold dilution of a 500x SYBR gold (Invitrogen) aliquot was 
prepared in T10E1 and 100μl were added per well. Fluorescence was read on Victor plate reader, using 
the settings for fluorescein (ex480 nm, em535 nm). 
For measuring adenovirus concentration, 50μl of the virus prep were mixed with 50μl of 0.1% SDS 
and were heat-inactivated at 56oC for 30 minutes. 2μl of the sample were added per well in quadruple 
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using the reverse pipetting technique and the average DNA concentration was calculated. Virus 
particle (vp) concentration for each virus prep was calculated using the following equation: 
𝑣𝑝
𝜇𝑙
=
𝐴𝑣𝑜𝑔𝑎𝑑𝑟𝑜′𝑠 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
∗ (𝐷𝑁𝐴 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛) 
- Vp = virus particles (the equation actually calculates DNA copy number),  
- Avogadro’s constant = 6.02214129*10^23,  
- molecular weight (in ng/mol); calculated for each virus separately using an online calculator 
(Paul Stothard , The Sequence Manipulation Suite: DNA molecular weight, 
http://www.bioinformatics.org/sms2/dna_mw.html, last accessed 05/2014) 
- DNA concentration (in ng/μl) calculated as described above 
An online DNA copy number calculator (using the DNA sequence and mass as input) is also 
available (endmemo.com » biology » DNA/RNA copy number, 
http://endmemo.com/bio/dnacopynum.php, last accessed 05/2014) 
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Shift of the negative population in flow cytometry 
A shift of the negative population was observed in flow cytometry when using the replicating viruses 
(Supplementary figure 1A). To prove that this indeed represents a shift, the following experiment was 
done. 10^6 HepG2 cells were seeded in a 6-well plate and infected at the same time with 10^8 vp of 
the EGFP expressing replication-competent vAd5wt(WTp-E1AΔ24). After a few hours the infected 
well was washed 10 times with PBS and 10^6 more HepG2 cells were added. Cells were harvested 
and analysed with flow cytometry the next day. It was shown that the uninfected cells had shifted 
away from the control uninfected population (Supplementary figure 1B). To test if this had to do with 
the harvesting/fixation process, cells from uninfected wells were mixed with cells from infected wells 
(Supplementary figure 2): (A) right after trypsinization, (B) during fixation with 2% PFA or (C) after 
fixation. Interestingly, just mixing the cells after trypsinization resulted in the same shift, while 
mixing during or after fixation did not affect the uninfected population. 
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Supplementary figures and photos 
Supplementary figure 1; Shift of the uninfected population in flow cytometry 
     
 
Supplementary figure 2; Shift of the uninfected population by mixing during harvesting 
 
 
 
 
 
- Uninfected cells 
- Infected cells 
- Mixed  right 
after 
trypsinization 
- Uninfected cells 
- Infected cells 
- Mixed during 
fixation with 
PFA 
- Uninfected cells 
- Infected cells 
- Mixed after 
fixation 
A B 
- Uninfected control 
- Infected with 
vAd5wt(WTp-E1AΔ24) 
- Uninfected control 
- Infected control 
- Well with uninfected 
HepG2 cells added 
A B C 
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Supplementary figure 3; Insertion of CMV-EGFP cassette                                                                 
(see page 28). Illustration made with Gene Construction Kit software. The scales of the plasmids and 
regions are modified for illustration purposes 
 
v
A
d
5
w
t(
E
G
F
P
) 
  
 76 
Supplementary figure 4; 2nd and 3rd recombineering step.                                                                    
See page 28. The scales of the plasmids and regions are modified for illustration purposes. 
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Supplementary figure 5; Time course of vAd5wt(EGFP) and vAd5/35(EGFP) in HCC cell lines 
 
 
 
 
 
 
 
2*10^5 cells were seeded in 24-well plates and infected the next day with 3*10^7 virus particles. 
Cells were harvested for flow cytometry at 3 time points; 30 hours, 40 hours and 48 hours post-
infection. Note the much lower transduction efficacy in HepG2 cells. Also note that even at 48 hours 
there is a significant overlap of the positive and negative populations in HepG2. 
 
30h 40h 48h 
30h 
40h 48h 
30h 
30h 
40h 
40h 
48h 
48h 
Huh7.5- infected with vAd5wt(EGFP) 
Huh7.5- infected with vAd5/35(EGFP) 
HepG2- infected with vAd5wt(EGFP) 
HepG2- infected with of Ad5/35(EGFP) 
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Supplementary figure 6; Co-infection of vAd5/3(EGFP) with vAd5wt(WTp-E1AΔ24)(no-EGFP) 
  
  
Pi; post infection                                                                                                                                                                     
The percentage of positive cells was determined by histogram subtraction (Overton method) after 
normalization so that the peaks (mode count) of the negative populations match.                                                
Unexpectedly, although the co-infection reduced the overlap between the positive and negative 
population the transduction efficacy remained unchanged.                                                                                     
The results were similar for all the fibre-modified viruses. 
HepG2 (co-infection) at 19h pi 
(about 42% positive) 
Huh7.5 (co-infection) at 19h pi 
(about 94% positive) 
HepG2 (Ad5/3 alone) at 40h pi 
       (about 38% positive) 
Huh7.5 (Ad5/3 alone) at 40h pi 
(about 94% positive) 
Uninfected sample 
Infected sample 
 
Uninfected sample 
Infected sample 
 
Uninfected sample 
Infected sample 
 
Uninfected sample 
Infected sample 
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Supplementary figure 7; Comparison of the fibre-modified viruses in primary ICCA cells. 
 
11 
4*10^5 cells were seeded in a 24 well. 30 hours later cells were infected with four 4-fold serial 
dilutions of the fibre-modified viruses. The highest dose was 6.4*10^9 virus particles (figure A). 
Figure B represent the histograms corresponding to wells infected with 4*10^8 virus particles. 
Uninfected sample 
- vAd5wt(EGFP)                            
- vAd5/3(EGFP)                   
- vAd5/RGD(EGFP
- vAd5/FMD(EGFP) 
- vAd5/35(EGFP) 
(A) 
(B) 
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Supplementary figure 8; Primary hepatocytes (cryptogenic cirrhosis liver) infected with 
vAd5wt(WTp-E1AΔ24) 
 
 
(A) Primary hepatocytes isolated by Dr E. Humphreys from a liver with cryptogenic cirrhosis. 
5*10^5 cells were seeded in 24-well plates (B) 17hours post-infection with 5*10^6 virus particles of 
vAd5wt(WTp-E1AΔ24). (C) Uninfected control (autofluorescent debris is seen)                                                                                                              
Note that at just 17 hours post-infection high levels of fluorescence are present suggesting virus 
replication. The other two viruses also resulted in visible fluorescence at 17 hours but of a lower 
intensity compared to that seen in (B) (Supplementary figure 9). 
A 
B C 
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Supplementary figure 9; Flow cytometry histograms of hepatocytes infected with the replicating 
viruses 
 
   
5*10^5 freshly isolated hepatocytes were seeded in a 24 well plate and infected the next day. Cells 
were harvested for flow cytometry 2 days later. These histograms represent infection with 5*10^6 
virus particles. Note the higher fluorescence intensity of the population infected with vAd5wt(WTp-
E1AΔ24). An example of the gating strategy is shown. 
- Uninfected control 
- vAd5wt(hTERTp-E1A) 
- vAd5wt(WTp-E1AΔ24) 
- vAd5wt(Ε2Fp-E1AΔ24) 
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Supplementary figure 10; Problems with the hepatocytes isolated from the marginal liver 
donor. 
  
   
   
(A) A well seeded with 5*10^4 hepatocytes. The hepatocytes cannot be seen due to large amount of 
debris. (B) After washing the wells with PBS (a variable number of cells might have been lost during 
this washing) (C) Cells infected with about 10^6 vp/well of vAd5wt(EGFP) and harvested 2 days 
later. Different gating strategies are shown. It was unclear which region represented the hepatocyte 
population. The presence of other cell populations cannot be excluded. 
A B 
C 
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Supplementary figure 11; ncCD40L better than wtCD40L? 
 
Two-tailed p values; **< 0.01, * < 0.05. P values calculated with Excel’s “two sample t-test 
assuming unequal variances”. It is possible that the small differences observed have to do with the 
very different particle-to-infectious units ratio of the two viruses. vAd5wt(ncCD40L) had a much 
higher particle-to-IU ratio according to the hexon staining titration (Table 4). Indeed, when the 
bottom graph was plotted based on vp/cell instead of IU/cell there was a better match between the 
two curves (Figure 23).  
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Supplementary figure 12; lack of antigen detection by the polyclonal antibodies used for IHC 
  
  
 
 
 
 
- CC-SW-I stained with 
the polyclonal anti-αvβ6 
- isotype control (rabbit) 
- CC-SW-I stained with 
53a.2 (against αvβ6)                                                
- mouse isotype control                                     
- rabbit isotype control 
 
- Huh7.5 stained with the 
polyclonal anti-DSG2       
- isotype control (rabbit) 
- Huh7.5 stained with 6D8 
(against DSG2)                                                  
- isotype control (mouse) 
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Supplementary figure 13; selected flow cytometry histograms from blocking experiments 
 
 
 
Blocking of vAd5/35(EGFP)- CC-LP-I 
Blocking of vAd5/FMD(EGFP)- CC-SW-I 
- Infected without antibody 
preincubation                        
- preincubated with 53a.2                                                                                                             
- preincubated with RMCB                    
- preincubated with L230 
- Infected without antibody 
preincubation                                     
- Preincubation with 53a2                 
- Preincubation with RMCB 
Blocking of vAd5/FMD(EGFP)- CC-LP-I 
- Infected without antibody 
preincubation                                     
- Preincubation with the polyclonal 
anti-CD46                                                       
- Preincubation with MEM-258 
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Supplementary photo 1; IHC of HCC for CAR. (A) CAR showing a bile canalicular staining pattern (arrows). (B) 
Focal expression of CAR (although in both cases lighter widespread cytoplasmic staining can also be seen) 
 
A 
B 
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Supplementary photo 2; IHC of HCC for CAR. (A) CAR downregulated in tumour but still 
present. (B) Higher magnification of the tumour part of A. (C)-(E) Expression of CAR by both 
tumour and margin. (F) CAR was not detected in this tumour. # tumour, * margin 
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Supplementary photo 3; CD40 and CD40L expression by HCC (#) and margin (*) 
(section from a liver with HCC and hepatitis C) 
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Supplementary photo 4; Staining for CD40 (top) and CD40L (bottom) (section from a liver 
with chronic hepatitis C) 
 
                   
Arrow: focal intralobular necrosis with lymphocyte infiltration. Portal triad: Bile ducts (*), portal vein (#), 
hepatic artery (+). The membrane staining pattern seen in the section stained with for CD40L, combined with 
the lack of staining of the stromal tissues, argue against the possibility of non-specific binding of the antibody. 
* * 
# 
+ 
